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Abstract
Aims. The major aims of the present work were to increase the understanding of cancer 
related fatigue with respect to assessment methodology, frequency and possible etiology. The 
validity of two fatigue instruments was evaluated and compared in order to enable an 
evaluation of the fatigue assessments in different patient cohorts. Secondly, the frequency and 
course of fatigue during curative cancer treatment, as well as the frequency of fatigue in 
cancer survivors were investigated in order to demonstrate the symptom burden during 
treatment and after ending curative treatment. The tertiary aim was to explore possible 
etiologic factors that may explain fatigue in cancer survivors.
Background: The long term survival of cancer patients has risen dramatically during the last 
decades. Several follow-up studies have shown that the long term side effects of curative 
treatment are more pronounced than first expected. During the last years much more attention 
have been given to the need for systematic follow up and assessment of long term effects on 
objective and subjective health after curative treatment. Fatigue is reported to be one of the 
most frequent and disturbing symptom in cancer patients in general, and is experienced by 
cancer patients at all stages of their disease. Fatigue is also observed as a subjective late effect 
in cancer survivors. The prevalence of chronic fatigue (elevated fatigue levels > 6 months) is 
2-3 times higher in Hodgkin´s Disease Survivors (HDS) than in the general population. 
Despite the high prevalence of fatigue, the etiology and causes of the symptom is not clear. 
Most studies of fatigue in cancer patients are cross sectional and of limited value when 
exploring the frequency and contributing factors to the etiology. Since fatigue is a subjective 
phenomenon, it is agreed that it should be measured by patients self assessment. Several 
instruments are developed for fatigue measurement, both uni - and multi - dimensional. As in 
research in general, the validity of the subjective outcomes are of crucial importance.  
Methods: Five different studies were conducted in order to meet the major aims. Two aspects 
of the validity of the fatigue scale in the health related quality of life (HRQoL) questionnaire 
EORTC QLQ-C30 were addressed, the dimensionality of the fatigue scale (FA) and the 
sensitivity of the FA. The instruments were evaluated in two different patient cohorts, a 
palliative patients cohort and a cohort of hematooncological malignancy patients after 
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curative treatment. A longitudinal follow up study of HRQoL and fatigue in lymphoma and 
leukaemia patient before, during and until three to five years post treatment with high dose 
chemotherapy and stem cell support was conducted in order to evaluate the trajectory of 
fatigue and HRQoL during and after treatment, and to compare symptom and function levels 
between the cohorts. The relationship between fatigue and late effects of pulmonary, cardiac 
and endocrine function as well as brain MRI abnormalities were investigated in order to 
explore possible etiologic factors of fatigue in lymphoma survivors after transplant therapy 
and in HDS after standard treatment.  
Findings: The EORTC QLQ-C30 fatigue scale is one - dimensional measuring physical 
fatigue. A floor/ceiling effect illustrated a poor sensitivity of the scale in patients with lowest 
respectively highest fatigue level. According to the longitudinal study lymphoma patients 
report more fatigue, poorer functioning and poorer quality of life as compared to leukaemia 
patients three to five years after post transplant and as compared to the general population. 
This pattern was also observed at baseline before transplant. Pulmonary dysfunction was 
associated with fatigue in HDS whereas cardiac and thyroid dysfunction as late effects after 
curative treatment did not explain high levels of fatigue in HDS. A questionable association 
between fatigue and thyroid and gonadal dysfunction were observed. Neither cytokines nor 
brain white matter lesions were associated with fatigue in HDS. 
Conclusion: The fatigue subscale, FA, of the EORTC QLQ C30 is measuring physical 
fatigue. The ability of FA to discriminate between patients with different levels of fatigue is 
poorer as compared to a fatigue specific instrument (Fatigue Questionnaire). The validation of 
instruments in different cohorts with differences in frequency and intensity of symptoms is 
important. 
As illustrated in earlier studies, fatigue is a prevalent symptom in lymphoma patients before 
and after treatment indicating that fatigue may be related to the lymphoma disease.  
Pulmonary late effects was predictor of fatigue in HDS, and the explanatory value of cardiac 
and endocrine late effects need further investigation. Follow-up program that extend 15-20 
years post treatment should be considered in order to explore the effect of clinical relevant 
medical late effects on subjective health including fatigue.
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Introduction
Preface
In Norway 24, 434 new cases of cancer were reported in 2004, 12, 919 in men and 11,515 in 
women, and approximately 50% are expected to be cured from the disease.1 The most common 
treatment modalities are surgery, chemotherapy and radiotherapy, often in combination 
depending upon the primary diagnosis, stage of the disease and other prognostic factors.
The prognosis for survival from cancer has steadily improved since the 1950s with a 5-year 
relative survival increasing from 25% to 50% in men, and from 37% to 58% in women. The 
improved prognosis is most pronounced in certain malignancies such as Hodgkin´s Disease 
(HD), testicular cancer and childhood cancers, with less pronounced improvement for the most 
common types of cancers such as breast, lung, prostate and gastrointestinal cancers.
By the improved prognosis and increasing number of survivors, studies of late effects have 
become more important. Late effects can mainly be divided into three categories. Firstly, there 
are the late somatic effects that include secondary cancers or affections of one or more organ 
systems. Secondly, there are the late effects of subjective nature, which include symptoms such 
as fatigue, pain and psychological phenomena. Thirdly, there are the late effects that may be 
categorized within the social domain which encounter difficulties in returning to normal life such 
as resuming work, difficulties in partnership or in participation in leisure activities.  
In general, late effects are more prevalent, serious and persistent than expected 2. Furthermore, 
how to rehabilitate and/or treat the survivors suffering from late effects lack systematic and 
adequate documentation.2 An essential issue which is hardly discussed in the literature is whether 
and how somatic late effects influence on the subjective health of cancer survivors.  
Quality of life (QoL) reflects the definition of health as proposed by the World Health 
Organization (WHO) in 1947 with emphasis on the subjective aspect of health and not only the 
absence of disease.3 During the 1980’s and 1990’s the concept of QoL became more directed 
towards health by the introduction of the term Health-Related Quality of Life (HRQoL). The 
latter operationalizes health as encompassing a social, a physical and a mental dimension. 
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HRQoL can be regarded as a narrowing of the concept QoL, and some therefore prefer the term 
subjective health. QoL as a health-related construct is recognized as a primary endpoint in the 
palliative phase of cancers, as a secondary endpoint in life-prolonging oncological treatment and 
is relevant for assessment of toxicity and side-effects in curative oncological treatment. Among 
cancer survivors, HRQoL captures the subjectively experienced consequences of cancer 
survivorship.
Fatigue is of subjective nature and therefore recognized as one domain within the HRQoL- 
concept. Fatigue is reported to be one of the most frequent and disturbing symptom in cancer 
patients in general, and our present knowledge of its prevalence indicates that fatigue is 
experienced by cancer patients at all stages of their diseases. Fatigue is also commonly observed 
as a subjective late effect in cancer survivors, and the prevalence of chronic fatigue is nearly 
three times higher in Hodgkin´s Disease survivors (HDS) than in the general population.4 Despite 
the frequency of fatigue and the increasing numbers of publications on cancer-related fatigue 
during the last decades, the etiology behind fatigue in general and cancer-related fatigue in 
particular is poorly understood. Further, most published studies on cancer-related fatigue have 
been cross-sectional and therefore of limited value in studying contributing factors and deciding 
which patients are in need of specific interventions. 
In order to prevent, treat, rehabilitate and/or support fatigued cancer patients, a better 
understanding of how fatigue develops over time and identification of underlying etiology is 
therefore warranted.
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Lymphomas 
The term “malignant lymphoma” was originally introduced by Billroth to describe neoplasm of 
lymphoid tissue.5 Lymphomas are traditionally divided into Hodgkin´s Disease (HD) and Non- 
Hodgkin´s Lymphoma (NHL) due to differences in histology and clinical course. Due to the 
recent improvement in the diagnostic of lymphomas, the name Hodgkin´s Disease is 
internationally mainly replaced with Hodgkin´s Lymphoma. However, since the patients 
described in this thesis were treated several years ago according to the current name Hodgkin´s 
Disease, the diagnosis in this thesis is designated Hodgkin´s Disease (HD). 
Hodgkin´s Disease 
Hodgkin´s Disease (HD) was first described in 1832 as a relatively uncommon malignancy.6 It is 
characterized by the presence of Sternberg-Reed cells, which are multinucleated giant cells 
surrounded by a variety of reactive bystander cells such as lymphocytes, macrophages, 
neutrophils, histocytes and plasma cells. As late as in 1940, HD was classified as an infectious 
disease.7 Epstein-Barr virus (EBV) may play a role in the pathogenesis of HD, and is subject of 
intense research. Thus, chronic viral infections as well as activation of cellular oncogenes, loss of 
tumour suppressor genes and the deregulators of several cytokines might be factors involved in 
the pathogenesis of HD.8 HD exists in two entities, classic HD (95% of the cases) and nodular 
lymphocytic predominance (paragranulome; 5% of the cases). The subgroups of classic HD are 
nodular sclerosis (45% of the cases), mixed cellularity (40%), lymphocytic predominance (5%) 
and lymphocytic depletion (5%). 
In year 2004, 120 new cases of HD were diagnosed in Norway. The incidence rates have been 
stable or decreased slightly over time (Fig.1).1 There is a bimodal age distribution, indicating that 
nearly 30% of new cases are found among subjects aged 20-29 years. The second peak is found 
among subjects 60 years or older (Fig.1).9 Approximately 1800 Norwegians are alive after 
curative treatment of HD.1
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Fig. 1. Incidence of Hodgkin´s Disease 1
HD primarily affects lymph nodes. Most patients develop enlarged lymph nodes in the cervical 
region (60%), the axillar regions, and the inguinal regions or in the abdomen. In advanced stages, 
the disease spreads to the spleen, bone marrow, liver or lung. A system for clinical staging of the 
disease was launched in 1960 (The Rye Classification),10 and modified in 1970 (Ann Arbor 
Staging System.11 The classification is based upon the spread to lymph node regions, to 
extralymphatic organs and whether the disease is located to one or both sides of the diaphragm 
(Table 1). Staging into sub stage A or B is based upon the absence (A) or presence (B) of one or 
more constitutional symptoms; fever, night sweat and weight loss >10% during the last 6 months. 
This staging system has been used throughout this thesis, and is available for both HD and for 
NHL.
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Table 1. Ann Arbor Staging System for Hodgkin’s Disease and Non Hodgkin´s Lymphoma 
Stage Criteria 
I Involvement of single lymph node region (I) or of single 
extralymphatic organ or site (IE) 
II Involvement of two or more lymph node regions on same side of the 
diaphragma alone (II) or with involvement of limited, contiguous 
extralymphatic organ or tissue (IIE) 
III
Involvement of lymph node regions on both side of diaphragma (III), 
which may include splen (IIIS) or limited, contiguous extralymphatic 
organ or site (IIIE), or both (IIIES). 
IV Multiple or disseminated foci of involvement of one or more 
extralymphatic organs or tissues, with or without lymphatic 
involvement. 
All cases are subclassified to indicate the absence (A) or the presence (B) of the systematic symptoms of significant 
fever, night sweats or unexplained weight loss exceeding 10% of normal body weight. 
Treatment and prognosis 
During the last three decades, as a result of advances in staging techniques and the successful 
development of effective therapeutic regimens, HD, a previously fatal malignancy, has become 
highly curable. The 5 years relative survival rate is approximately 75% for all cases. The age at 
diagnosis is a highly significant prognostic factor, with improved survival rate for patients 
younger than 65 years of age at time of diagnosis. 
The treatment principles for HD in Norway have been relatively unchanged during the last 15 
years. Stage I or II above diaphragm is most frequent, and patients without risk factors 
(unfavourable prognostic variables) have until recently been treated with radiotherapy alone 
(most often mantle field). Today, chemotherapy is standard combined with radiotherapy. Patients 
with risk factors have been and still are treated with combined chemotherapy and radiotherapy. 
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Treatment of stage III and IV basically include chemotherapy, eventually added by radiotherapy 
similar to those without risk factors.  
Radiotherapy
In the 1960s, the use of high-dose fractionated large-field irradiation provided the first high cure 
rates for patients with limited disease.12 Based upon knowledge of patterns of spread of the 
disease, the radiotherapy was divided into two major volumes: 1) The mantle field including the 
lymph nodes of the neck, axillae and mediastinum, and 2) The inverted Y-field including the 
paraaortic and pelvic area. A continuous revision of the radiotherapy techniques and better 
knowledge of response and radiotherapy-related toxicity, have lead to further refinements of 
fields and dosages. Today the field definitions are more functional, and the following fields are 
standard: 1) Involved field, which include the involved lymph nodes and the other lymph nodes 
within the same lymph node region and 2) Extended field, which include involved field as well as 
the adjacent lymph node regions. The latest within radiotherapy is the involved node field, which 
include the affected lymph node only. Fractional doses of 2,0 Gray (Gy) (from 1980 until mid 
1984) or 1,8 Gy (from 1984 and onwards) given 5 days a week to a mean total dose of 40,6 Gy 
(range 40-42) have been standard. Today the standard radiation dose for HD is 1,75 Gy to a total 
dose of 29,75 Gy. The patients included in this thesis have mainly been treated according to the 
standard treatment regimen in 1970`s and 1980`s (2 Gy, alternatively 1,8 Gy). 
Chemotherapy
The introduction of combination chemotherapy was the second important step to improve the 
survival rates of HD. In 1964 investigators at the National Cancer Institute developed a four-drug 
combination chemotherapy program, MOPP (vincristine, procarbazine, mustine, and prednisone). 
This landmark study established the curability of more than 50% of patients with stage III and 
IV, and was since then the gold standard for the treatment of advanced disease.13 The acute side 
effects of MOPP, primarily gastrointestinal and neurological toxicity, required investigation of 
alternative regimens with the desire to obtain equivalent or improved results with less toxicity. 
Alternative regimens have been COPP replacing mustine by cyclophosphamid, or ChlVPP 
(chlorambucil, vinblastine, procarbazine, and prednisone). Since late 1970s the ABDV – regimen 
(doxorubicin, bleomycin, vinblastine and dacarbazine) has gained an important position in the 
treatment of HD. The ABDV-regimen has documented improved effectiveness and less toxicity 
as compared to the MOPP-regimen.14 The ABVD is the standard regimen today (two or four 
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cycles), in case of insufficient response/progression, BEACOPP (cyclophosphamid, doxorubicin, 
etoposid, procarbazin, prednisone, vincristine, bleomycin) is the treatment of choice. For patients 
above 60 years, the CHOP-regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) 
and radiotherapy is standard. Details to the treatment regimens are given in the national treatment 
protocol (Nasjonale handlingsplan for maligne lymfomer; 2003, revised in 2004 and 2006). 
Non-Hodgkin´s Lymphoma 
The Non-Hodgkin´s Lymphomas (NHL) constitute a heterogeneous group of malignant 
neoplasma arising from B-and T-lymphocytes. The histological subtypes are numerous, the 
localization in extra nodal tissues, its capacity to remain localized or to disseminate throughout 
the body make this malignancy less predictable than HD. 
NHL is more prevalent than HD. In Norway more than 700 new cases of NHL are diagnosed 
annually.1 The incidence of NHL is steadily increasing in all countries, and the incidence among 
men is higher as compared to women (Fig.2). Dramatic changes and improvements with the 
diagnostic of lymphomas in general and changes in the classification of HD and NHL have had 
an impact on the changing trends. New improvements within immunology and cytogenetic/DNA-
technology and in particular the use of immunphenotyping in the diagnostic have improved the 
classification system and ensured a correct diagnosis. 
Fig. 2. Incidence of Non-Hodgkin´s Lymphoma 1
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Several histological classification systems have been proposed for NHL. The Kiel classification 
divides the NHL into the cell type of origin, principally T-cell or B-cell origin, and into low-
grade and high-grade lymphomas, and has been used in Norway since the 1980s. In 1994 the 
REAL (Revised European-American Lymphoma) - classification was published, a revised 
classification system which quickly gained worldwide approval. In 2001 this was replaced by the 
WHO classification of lymphomas, which include both NHL and HD.14, 15 In the WHO 
classification, the subdivision of low grade and high grade lymphoma is abandoned. Diffuse large 
B cell lymphoma, peripheral T cell lymphoma and follicular lymphoma (low grade lymphoma) is 
the main subgroups in the WHO classification group. Patients with NHL included in this thesis 
are classified by the Kiel-classification system (Table 2). For the staging of NHL the Ann Arbor 
staging system is used (Table 1). 
Table 2. Kiel classification of Non-Hodgkin´s Lymphoma 
B-Cell Neoplasms T-Cell Neoplasms 
Low-Grade Malignant Lymphoma 
x Lymphocytic 
x Lymphomaplasmacytic/cytoid 
x Plasmacytic 
x Centroblastic-centrocytic
x Centrocytic (mantle cell) 
x Monocytoid
Low-Grade malignant Lymphoma 
x Lymphocytic 
x Small-cell cerebriform (mycosis 
fungoides, Sezary syndrome) 
x Lymphoepithelioid 
x Angioimmunoblastic
x T-zone lymphoma 
x Pleomorphic, small cell 
High-Grade Malignant Lymphoma 
x Centroblastic
x Immunoblastic
x Burkitts Lymphoma 
x Large-cell anaplastic 
x Lymphobastic
High-Grade Malignant Lymphoma 
x Pleomorphic, medium sized and 
large cell 
x T-immunoblastic 
x Large-cell anaplstic 
x T Lymphoblastic
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Treatment and prognosis 
It has been a dramatic development within the treatment of NHL during the last 10 to 15 years. 
Chemotherapy is the most important treatment modality for NHL, and extended use of 
combination chemotherapy regimen and the introduction of immunotherapy have improved the 
treatment results. Despite improvements in treatment, the mortality rates increases. While there is 
no gender differences in mortality rates of HD, women with NHL have somewhat better 5 years 
survival as compared to men (60% vs 55%). Stage, histological subtype and age are other 
important prognostic factors. The several treatment regimens for the different NHL are presented 
in the national treatment protocol (Nasjonal Handlingsplan for maligne lymfomer, 2003, revised 
in 2004 and 2006). 
Chemotherapy
The majority of the patients with NHL (80-90%) have extensive disease. For patients with 
intermediate or high-grade NHL the CHOP-regimen have been considered as standard therapy. 
For patients with localized disease (stage I and II) most patients can be cured with chemotherapy 
only, as can 30-40% of patients with stage III and IV.16 In order to improve the outcome, 
increasingly complex regimens were developed during the 1980s such as methotrexate, 
leucoverin, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin (MACOP-B) 
- combination. Today, research within the molecular biology and target therapy has developed 
new treatment modalities also for lymphoma treatment. Immunotherapy with rituximab, a 
monoclonal antibody to the CD 20 antigene is today included in the standard treatment regimen 
in combination with CHOP for most of the NHL (CD20 positive).  
Radiation therapy 
The use of radiotherapy in the treatment of NHL depends upon histology, disease stage, and 
physiologic status of the patient. With more effective chemotherapy regimens, the technique of 
radiotherapy has been modified or even eliminated under some circumstances. It is included as 
standard treatment in combination with chemotherapy for patients with NHL stage I/II, or a 
single treatment modality for indolent NHL stage I/II, limited disease. The fields are to a great 
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extent similar to the fields used for HD. Fractional dosage of 2 Gy and a total dosage of 40 Gy 
are the most frequently applied doses. 
High dose therapy and stem cell transplantation 
Relapses in lymphoma patients younger than 65 years will be considered for high dose 
chemotherapy (HDC) and stem cell transplantation (SCT). The stem cells can be harvested from 
the patients pre-transplant, an autologous transplantation, or from an HLA (human leucocyte 
antigen)-matched donor, an allogenic transplantation. Bone marrow derived stem cells are 
considered as the classical stem cell source. Today, the peripheral blood progenitors (PBSC) is 
used as an alternative source for haematopoietic reconstitution, especially in autologous 
transplantation. Prior to the infusion of stem cells, the patients receive high doses of 
chemotherapy, in some patients in combination with total body irradiation (TBI) as part of the 
preparative regimen. In Norway, patients are treated with MIME (mitoguazon, ifosphamide, 
methotrexate, etoposid) as induction chemotherapy regimen, but cyclophosphamide containing 
chemotherapy regimen have also been applied. TBI has for many years been included in the 
preparative regime for patients undergoing transplant for lymphomas, especially for 
transplantation in patients with low-grade and lymphoblast lymphoma. However, many patients 
have received thoracic irradiation prior as part of the primary treatment, and due to many trials 
indicating a high risk of pulmonary toxicity related to radiotherapy, the use of TBI in HD is 
reduced.17
Late effects in patients treated for HD and NHL  
Organ toxicities of the treatment modalities of HD and NHL are relatively well documented,18-20
and studies of late effects from HD in children and other childhood cancers such as leukaemia 
and brain tumors have provided the foundation for research on late effects and long-term cancer 
survivorship.2 However, the long-term and late effects of cancer and its treatment remain poorly 
documented and understood among those diagnosed as adults. Research on late effects in patients 
cured for cancer is challenging in many aspects and implies more than the study of organ toxicity 
alone. Although cancer survivors are living longer, limited knowledge exists about health status, 
functioning and quality of life for most of the patients treated for cancer.2 The complexities of the 
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late effects themselves, the impact of late effects on their physical and psychosocial health and on 
HRQoL, and the effect of aging, lifestyle, behaviour and comorbidity on health status challenges 
the researchers in finding causal factors related to the outcomes observed. In particular there is a 
paucity of longitudinal cohort studies to link specific treatment regimens to late physical and 
psychosocial effects. Who are at risk for certain late effects, and who can be prevented are some 
of many questions related to cancer survivorship. Thus, it is not possible to describe the natural 
history of these events for future patients and for the health care providers. 
Regarding lymphoma survivors most of the information on late medical effects stem from studies 
of HD treated by radiotherapy.20 The majority of NHL patients are treated by chemotherapy. 
Studying late medical effects in NHL patients is more complicated. The age at peak incidence of 
NHL is above 40 years, for some subtypes even above 60 years. As the morbidity for most 
diseases increases by age, separating specific late effects from general morbidity poses 
methodological challenges related to design of studies and use of controls. Table 3 illustrates 
some described late medical effects among survivors of HD. 
Table 3. Late medical effects observed in patients cured for Hodgkin’s Disease 
Late effect Causes and risk factors 
Immunologic dysfunction Underlying disease, therapy 
Herpes zoster or varicella Underlying disease, therapy 
Pneumococcal sepsis Splenectomy, functional asplenia after RT 
Nonlymphocytic leukemia Therapy, older than 40 y 
Myelodysplastic syndroms Therapy, older than 40 y 
Non Hodgkin’s lymphoma Therapy
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Solid tumours Direct or indirect RT exposure 
Thymic hyperplasia Underlying disease, therapy 
Hypothyroidism Direct or indirect RT exposure 
Thyroid cancer 
Direct or indirect RT exposure, chronic 
thyroid stimulation 
Male infertility Therapy, underlying disease 
Male impotence Therapy, underlying disease 
Female infertility Therapy
Female dyspareunia Therapy, underlying disease 
Pericarditis, acute Mediastinal RT, recall with CT  after RT 
Pericarditis, chronic Mediastinal RT 
Cardiomyopathy Mediastinal RT, doxoxrubicin, recall with 
CT after RT 
Pneumonitis, acute Direct or indirect RT, bleomycin, 
nitrosoureas, recall with CT after RT 
Pneumonitis, chronic Same as above 
Avascular necrosis Steroid therapy, underlying disease (?) 
Growth retardation Pediatric RT 
Dental caries Salivary change after RT 
RT: Radiation therapy; CT: chemotherapy 21
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Second malignancies
Second malignancies are considered the most serious late effect observed in survivors of HD, and 
are currently the primary cause of mortality of these patients.22 These late effects are probably the 
best documented late medical effects due to the valid comparison data obtained from the cancer 
registries. A long follow up period is required to obtain incidence data, and another challenge is 
that many patients have been treated with obsolete therapeutic regimens (i.e. mantle or extended 
field, MOPP chemotherapy). 
Second malignancies after HD can be divided into three main categories: leukaemia, NHL and 
solid tumours. The risk of solid tumors exceeds that of leukaemia, and lung and breast cancer are 
the most common cancer diagnosis.23, 24 Radiotherapy is the most important risk factor for both 
types of cancer. Other risk factors are age at first treatment, treatment modality, and radiation 
field and dose.23, 25 Sarcoma, malignant melanoma, and thyroid cancer are other cancers which 
are found more frequent in patients treated for HD as compared to the general population.24, 26
Survivors of NHL are at increased risk for second malignancy, however much less than among 
HDS. This may be related to older age at diagnosis and less use of radiotherapy. An excess risk 
of leukemia and bladder cancer has been demonstrated to be treatment related, especially high 
dose cyclophosphamid regimen. 
A strongly increased risk of leukaemia and myelodysplastic syndrome (MDS) following 
autologous bone marrow transplantation or peripheral stem cell transplantation for both NHL and 
HD is reported.27
Cardiovascular late effects 
Cardiovascular diseases are considered the commonest non-malignant sources of excess 
morbidity and mortality among HDS and survivors of NHL, and provide difficult diagnostic and 
therapeutic dilemmas in the long-term care of patients after therapy.28 The occurrence of 
radiation-induced heart diseases among patients treated for HD was recognized during the early 
era of high-dose mantle field irradiation. The clinical manifestations in the cardiovascular system 
range from asymptomatic pericardial effusion to fatal pancarditis, cardiomyopathy, myocardial 
infarction and vascular stenosis and thrombosis.20
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A three fold increase in relative risk of cardiac death in patients treated for HD is reported, and 
the majority of the cardiac deaths are related to myocardial infarction probably due to 
development of premature coronary artery atherosclerosis.29 The Stanford study also 
demonstrated a clear association with mediastinal irradiation and radiation dose, in that 
mediastinal irradiation to a dose of 30 Gy or less conferred no excess risk of cardiac complication 
and deaths. Young age at treatment and increasing time after completion of treatment is also 
associated with increased risk of myocardial infarction and death. 
It is unclear whether or not the use of chemotherapy, in particular the increasing use of 
anthracyclines, will have a long-term effect on cardiac diseases. Anthracyclines are important 
antineoplastic drugs frequently used in combination with doxorubicin as one of the key 
component in the treatment of HD and NHL.30 Cardiomyopathia and congestive heart failure are 
dose-limiting factors, which usually occur after doses greater than 550 mg/m2. A few studies 
have explored late cardiotoxicity after treatment with doxorubicin in adult HD and NHL 
patients.31, 32 Most studies have been performed in children or in patients treated for acute 
leukaemia or breast cancer. In a study of long term adult survivors of lymphomas treated by 
doxorubicin, subclinical cardiac abnormalities were observed in the absence of congestive heart 
failure, and even after moderate doses of antracyclines.33 Lund et al described abnormal left sided 
valvular regurgitation in one fourth of HDS investigated after mediastinal radiotherapy, and 
females were at increased risk.34 The gender differences could not be explained by treatment-
related differences or differences in baseline characteristics. 
The risks of complications that lead to chronic heart diseases and premature mortality have been 
appreciated for more than one decade, and many centers and clinical trial groups have instituted 
changes in treatment programs in order to minimize these risks.22, 31 The introduction of 
subcarinal blocking into the mantle field in 1972 in order to limit the radiation dose to myocard is 
one example. However, still important questions remain regarding long term effects. Few data 
exists on long-term excess risks of chemotherapy alone, while many series include several 
hundred patients treated with radiotherapy with median follow ups in excess of 10 years.24, 35
Issues related to radiation dose effect are another important issue, and of particular interest since 
radiation remains the most effective single treatment modality for the treatment of HD. Finally, 
how should the patients be followed up after completition of therapy? Is it possible for the single 
oncologists to continue to follow the patients after treatment taking into consideration the 
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structure of the health care management, and the increasing number of cancer patients and cancer 
survivors? When do the patients have suspicious symptoms that demand a doctoral consult? 
Screening studies in detecting cardiac abnormalities in patients treated for HD is one possibility, 
however the value of such screening is unclear.
Pulmonary late effects 
Pulmonary toxicity after radiation therapy for HD vary widely in presentation and severity and 
relate to volume of lung radiated, total radiation dose, dose rate, shielding techniques, radiation 
quality and undefined host factors that affect the extent of normal tissue reaction to irradiation.29
The adverse effects range from acute interstitial pneumonitis to chronic lung injury such as 
pulmonary fibrosis and recurrent pleural effusions.36, 37 Acute radiation pneumonitis can occur 
after radiation doses of more than 40 Gy to focal lung volumes or after lower doses (15-20 Gy) 
administered to whole lung and when combined with chemotherapy.38 Chronic lung injury 
including pulmonary fibrosis and late recurring pleural effusions are reported to be related to 
high-dose, large-fraction therapy. The use of bleomycin- and anthracyclines-containing 
chemotherapy regimens such as ABVD are reported to enhance both short-term and chronic 
pulmonary toxicity from radiation therapy.39
The evaluation of the pulmonary status long after treatment for HD has however revealed 
different results.29 Hassink et al reported significant pulmonary function abnormalities in HDS 14 
years after radiotherapy with pulmonary symptoms such as dyspnoe reported by some patients.40
Lund et al reported that nearly 30% of the 116 patients evaluated more than 5 years after HD 
therapy had symptomatic excertional dyspnoe and diminished lung capacity, forced vital 
capacity, forced expiratory volume and carbon monoxide diffusing capacity on pulmonary 
function tests.41 The findings were associated with the combination of thoracic radiotherapy and 
bleomycin- or anthracycline based chemotherapy regimen, and are consistent with others studies 
of patients treated with these combined modality treatment.39, 42, 43 Mantle field radiotherapy 
alone is found to be the most important factor associated with chronic reduction of forced vital 
capacity and diffusion capacity. In the absence of radiotherapy, bleomycin-induced pulmonary 
changes are usually mild and reverse over time, although Canellos et al reported clinically 
significant severe pulmonary toxicity in 6% of 115 patients treated with ABVD chemotherapy.14, 
39
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Endocrine late effects 
Different endocrine abnormalities are observed after treatment for HD. Thyroid abnormalities 
attributed to HD treatment include hypothyroidism, hyperthyroidism and thyroid malignancies. 
These abnormalities are perhaps the most frequent clinical problems requiring evaluation and 
intervention after HD treatment with irradiation to cervical region and upper mediastinum. A 20-
year actuarial risk of thyroid abnormalities of 50% is reported.42, 44 Hypothyroidism is the 
commonest of these abnormalities with an incidence between 31%-90%.42, 44 The majority of the 
patients are reported to have subclinical hypothyroidism with an abnormal elevation of thyroid-
stimulating hormone and normal FT4 level. This has been a common finding in case of 
biochemical screening of HDS that have been irradiated, and the findings have been variably 
associated with clinical signs and symptoms of hypothyroidism.29 Post irradiation 
hypothyroidism most often develop within the first 5 years after treatment, but some patients may 
develop hypothyroidism after 20 years or later. This challenges the physicians responsible for the 
follow up, how to diagnosticate correctly, when to start substitution therapy, and how to evaluate 
the effects of treatment.  
Gonadal dysfunction is a well-known complication in the management of HD. Earlier, with 
extended field radiotherapy as a major treatment modality, gonadal dysfunction in women was a 
sufficiently significant problem to make oophoropexy a popular procedure in order to avoid 
infertility.45 Pelvic radiation is an uncommon treatment modality today. The incidence of 
chemotherapy induced menopause in women varies by age. Patients above 40 years at the time of 
chemotherapy will frequently display induced menopause with related symptoms. Most patients 
under the age of 30 at the time of chemotherapy will remain fertile and over time regain normal 
menstruation.46 The use of MOPP like regimen are most associated with irregular menstrual 
function and increase in follicular-stimulating hormone (FSH) and luteinizing hormone (LH), 
whereas the ABVD seems to spare menstrual function and fertility in women. 
Infertility in males is a major complication after chemotherapy for HD. The possibility to recover 
normal spermatogenesis depends upon the type of chemotherapy regimen. After MOPP-like 
regimens recovery of spermatogenesis after a full course of chemotherapy is unusual, the chances 
are reported to be 5-14%. The FSH and LH will often be increased after therapy, although 
testosterone levels remain normal. In contrast, nearly all patients receiving the present standard 
chemotherapy regimen (ABVD) will eventually recover normal spermatogenesis.47
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Immunological late effects 
In cancer patients, the immune system may be altered by the underlying malignant disease or by 
the treatment. Long term immunosuppressive effects in patients treated for HD have been 
demonstrated after both radiation therapy, chemotherapy and combined modality treatment.48-50
These long term effects include decrease in the number or function of the T lymphocytes, 
especially the helper T-cell subset, as well as decreased response to peripheral blood lymphocytes 
to mitogens. Abnormalities of the cellular immune system in even untreated patients with HD is 
also documented.48, 50 This may explain the increased susceptibility for certain infections such as 
Herpes Zoster and tuberculosis, that may even appear in untreated HD patients. However, both 
chemotherapy and radiotherapy, splenectomy or splenic radiotherapy, may accentuate 
immunosuppresive effects and increase the risk of serious bacterial and viral infections. Herpes 
Zoster is the most common infectious disease in patients treated for HD, and the risk is highest 
within the first two years after ended therapy, however for some patients remains a life long risk. 
A long-term infectious risk also exists for gram positive S. pneumoniae and meningococcus 
which may cause fatal sepsis. For splenectomised patients a potential high long term risk for this 
infection will remain in the follow up.51
Neurological and neuropsychological late effects 
Several of the chemotherapeutic agents used in the treatment of HD and NHL can cause 
neurotoxicity alone, or in combination with radiation therapy. The most common chemotherapy 
agents used in the treatment of HD/NHL that have been associated with neurotoxicity are the 
vinca alkyloids such as vincristine and vinblastin. Neurotoxicity is caused by destruction of 
neurotubulus, most often presented as peripheral neuropathy with sensibility loss and impaired 
muscle strength.52 Cytarabine and methotrexate administered intravenously or intrathecally can 
cause meningeal irritation, paresis, encephalopathy or memory loss. Radiotherapy of the CNS 
increase the risk of neurotoxicty and is associated with encephalopathy and deficits in cognitive 
function.53
As demonstrated in recent reviews of the literature, cognitive deficits have been recognized as a 
problem among adult cancer survivors.53, 54 55 The most frequently reported cognitive domains 
being vulnerable to chemotherapy are attention, memory and executive functions, which all may 
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affect the activities of daily living, educational and working abilities. Cognitive deficits may 
therefore have dramatic effects on patients HRQoL, and ability to function even when the 
cognitive impairments are mild. Subtle changes are however difficult to identify because of lack 
of appropriate measures.56 Studies of breast cancer patients treated with high dose chemotherapy 
and autologous stem cell support reported more cognitive impairments and impaired HRQoL 2 
years after therapy as compared to those treated with standard chemotherapy.57 Additionally, 
more late cognitive impairments were observed in the latter group as compared to those not 
treated with chemotherapy. Cull et al reported in her study of adult disease free lymphoma 
patients or > 6months after therapy that those who reported cognitive problems such as memory 
and concentrating difficulties also reported more anxiety, depression and fatigue indicating an 
additional methodology challenge in evaluating impairments in higher mental function in cancer 
survivors.58
Late effects after high dose therapy and stem cell transplantation 
Patients treated with high dose therapy and stem cell transplantation are at increased risk for late 
effects both associated to the primary disease, the primary treatment and the high dose therapy 
per se. In general, the incidence of complications after high dose therapy is similar to those 
reported after standard therapy. A major concern is the possibility to develop myelodysplasia or 
acute myeloid leukaemia, and in particular after TBI.27 Hypothyroidism, sexual dysfunction and 
late infections such as Herpes zoster, pneumonia and infections in the urinary tract are frequent 
complications in lymphoma patients after BMT or ASCT.59
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Quality of life and health related quality of life 
Assessment 
HRQoL are subjective and consequently not directly observable or measurable. HRQoL are most 
commonly measured by questionnaires that are filled in by the patients. The instruments may be 
generic, in order to asses HRQoL in general populations; disease specific e.g. developed for 
cancer patients or domain specific assessing symptoms such as fatigue.60 The instrument needs to 
fulfil a set of requirements to produce valid and reliable results in clinical research. Most 
important are the basic properties, i.e. validity, reliability, sensitivity and responsiveness.61
Reliability refers to the accuracy and consistency of the measure. The more reliable a measure is, 
the lower is the element of random error. Validity is the degree to which the measure reflects 
what it is intended to measure. Sensitivity and responsiveness are closely related, and whereas 
sensitivity refers to the ability to detect differences between patients or groups of patients, 
responsiveness is the ability of a measure to detect underlying change within the patients.61
Several HRQoL instruments are developed and the most commonly used in cancer patients is the 
EORTC QLQ-C30.62 It is composed of five functional scales (physical, emotional, cognitive, 
social, role), three symptom scales (fatigue, pain, nausea) and five single items measuring 
dyspnoe, vomiting, appetite loss, constipation and financial impact of disease. Additionally 
global health and overall quality of life is measured (see appendix for the entire questionnaire). 
Fatigue
Concept and terminology 
Fatigue is commonly defined as a non-specific and subjective feeling of tiredness, physically 
and/or mentally.63 The multidimensionality of fatigue is partly grounded on theoretical and 
empirical data from cancer patients,64-66 patients with non-malignant diseases,67, 68 as well as 
disease-free cancer survivors.4, 69, 70 There are a number of current debates related to the number 
and types of dimensions. It is most commonly to divide fatigue into two dimensions, mental and 
physical fatigue, however, others have also been proposed.64
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Fatigue can be acute or chronic. Acute fatigue includes for example the subjective feeling of 
being ill during a common flu, the feeling of diminished energy during radiotherapy or the 
feeling of exhaustion after physical exercise. Fatigue lasting for 6 months or longer is by most 
researchers defined as chronic.71 In order to understand the concept and to plan treatment, an 
extensive understanding of the underlying pathophysiology (i.e. causal factors). These 
mechanisms are often more easily detected in acute than in chronic fatigue. Chronic fatigue may 
vary over time in intensity, being context dependent and occur in varying frequency and intensity 
in well defined cohorts. Chronic fatigue will in most patients also include the effects of 
behavioural adaption over time.  
Assessment of fatigue 
Fatigue was regarded as a central medical symptom during the second half of the 19th century.63
72 Several approaches to measurement of fatigue have been used throughout the history such as 
observation, self-rating and objective tests.65, 73-75 Self rating measures are the gold standard and 
most commonly used today. The measures can be divided into single –item and multi-item 
instruments. The latter might be uni- or multidimensional. As mentioned previously, fatigue is 
often included as a domain within the HRQoL concept. Subscales measuring fatigue are therefore 
included in the generic HRQoL instruments, such as the SF-36 (i.e. not specific to any population 
or disease), as well as disease-specific instruments, such as the EORTC QLQ-C30.76 62
Several domain specific instruments specifically designed for measuring fatigue are also 
available.66, 77-81 Although most researchers state that fatigue is a multidimensional phenomenon, 
the number and content of dimensions (as already discussed in this thesis) are debated, and the 
various instruments reflect this. However, all present fatigue-measures include physical fatigue, 
which corresponds to the subjective feeling of being exhausted and lacking energy. In advanced 
metastatic disease, fatigue is commonly viewed as uni-dimensional, ie a reflection of general 
illness.82 Due to clinical experience and descriptive studies, palliative cancer patients report not 
only impaired physical performance, but they are also mentally alert with concentration 
difficulties and impaired memory, symptoms of mental fatigue. Unidimensional fatigue measures 
will probably exclude the possibility of a complete description of the fatigue experience of cancer 
patients.
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The prevalence of fatigue 
Fatigue in the general population 
Fatigue is a common complaint within the general population, with approximately 10% reporting 
a clinical significant level of fatigue.74, 83, 84 Fatigue is also highly prevalent among attenders in the 
primary health care (20-30%).85
Fatigue in somatic and mental diseases 
Fatigue is a major symptom in a whole range of somatic conditions, including acute viral and 
bacterial infections as well as neurological diseases, such as multiple sclerosis (MS), post 
poliomyelitis and post stroke. It is a cardinal symptom of chronic inflammatory diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, in kidney disease, in chronic heart failure and 
chronic obstructive pulmonary diseases.65, 68, 86-90
Fatigue is one of the nine criteria for major depression according to the DSM-IV.91 Fatigue 
correlates strongly with psychological distress in the general population.84 Depression and anxiety 
are also the most stable associations of chronic fatigue in primary care.63 In somatically ill patients, 
however, it is difficult to differ between depressive and fatigue symptoms. Fatigue may be a result of 
depressed mood, and a person who continuously perceives his or her energy as insufficient may 
become depressed. 92
Fatigue in cancer patients 
Fatigue has been described as a nearly universal symptom among cancer patients.93 It might be a 
first symptom of cancer, a side effect of cancer treatment or a prominent symptom of terminal 
disease. Fatigue is highly prevalent among cancer patients undergoing cytotoxic chemotherapy, 
radiation therapy, bone marrow transplant or treatment with biological response modifiers.65, 94-101
However, there is a lack of systematic studies addressing the prevalence across diagnoses and phases 
of the disease, the intergroup (diagnosis) variability in cancer as well as variations according to stage 
of disease and phase of the illness. A limited number of studies of fatigue in relation to type of 
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treatment are available.65, 97, 100-104 The sample sizes in these studies are small, and fatigue has been 
measured with different instrument and at different point in time according to treatment and 
diagnosis, and suitable comparison groups are seldom included. This makes comparison difficult 
between studies. Most of the studies are cross-sectional, and valid estimation of the duration is 
therefore seldom available.105, 106
One of the first studies addressing fatigue in cancer survivors were published in 1986.107 In this 
follow up study of HDS, 37% reported that the energy level was not returned to normal after end 
of therapy. Relatively few studies have later investigated fatigue in cancer survivors. Studies of 
adult long term survivors of childhood cancer have not demonstrated long-lasting fatigue after 
cancer cure.105, 108 Various data exist on fatigue in survivors of breast cancer. Lindley et at failed to 
demonstrate increased fatigue post treatment for early stage breast cancer.106 A recent longitudinal 
study of fatigue in long term breast carcinoma survivors indicated that 34% of the women were 
fatigued 5-10 years after diagnosis.109 Among long-term survivors of testicular cancer, 16% reported 
chronic fatigue.110 Fatigue is still reported to be a frequent symptom among HDS, and affects up to 
1/4 of the HDS.4, 107, 111 The symptom seems to persist several years after treatment.112 Except for 
higher level of fatigue in patients with stage IB/IIB of the disease, no relationship between fatigue 
and disease characteristics or type of treatment have been found.4 A recent study support these 
finding in that no association between fatigue and type of treatment over time were found.113
Different instruments used to measure fatigue, choice of comparison groups and cross sectional 
designs limit the possibility to draw firm conclusions. 
Possible etiology of fatigue  
General comments 
Many possible causes and factors related to the etiology of fatigue have been suggested in the 
literature, but relative few hypotheses have however been testable regarding the etiology of this 
symptom. Take into consideration the prevalence of the symptoms across quite different patient 
groups, it is likely that several mechanisms underlie fatigue, and that they probably vary between 
populations as well as within populations.  
Almost all studies of fatigue are cross-sectional, which makes it difficult to draw causal 
relationships. What might look like highly significant predictors in cross-sectional studies might be 
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confounding effects. Confounding implies that underlying factor(s) explain both the predictor and 
the outcome (i.e. fatigue). The cancer disease itself might be the confounder in cancer patients with 
active disease. This is supported by a study of pain and fatigue in elderly cancer patients, which 
demonstrated that both fatigue and pain were explained by the same disease variables.114
Inactivity, sleep disturbances and psychological distress are commonly observed in most diseases, 
and have all been associated with fatigue. Other factors that have been associated with fatigue such 
as pain and anaemia are not necessarily observed in all diseases, or may be relevant contributing 
factors in cancer patients but not in disease free cancer patients. In cancer patients without active 
disease other factors may play important roles such as pathophysiologic mechanisms to disease- and 
treatment related late effect (i.e. alterations in immune and neuroendocrine function). Medical 
conditions, genetic factors and personality characteristics are not investigated extensively.
Few studies have documented a causal relationship between a pathological process (for example 
a particular late effect) and cancer-related fatigue. For some symptoms such as nausea and pain 
there are specific neuronal pathways, which convey the message from the affected part of the 
body to the brain where the information is processed and eventually expressed. In our clinical 
settings we can therefore assume that the subjective sensation (pain) reflects an underlying 
pathological process (for example bone metastasis) that has activated the neuronal pathway, and 
one will treat the bone metastasis, for example with radiotherapy, to relief the pain. However, no 
such neuronal pathway has been documented for cancer-related fatigue. Fig. 3 gives an overview 
over possible relevant factors for developing cancer-related fatigue.  
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Cancer related fatigue 
Cancer treatment complications 
x Anemia 
x Sepsis
x Pulmonary and cardiac 
disorders 
x Renal/hepatic failure 
x Metabolic complications 
x Dehydration
x Hypoxie
x Neuromuscular disorders 
Psychosocial factors 
x Coping with chronic 
illness 
x Anxiety 
x Depression 
Comorbid symptoms 
x Pain
x Nausea 
x Dyspnoe 
x Sleep disturbance 
x Deconditioning 
Comorbid medical conditions 
x Congestive heart failure 
x Neurologic disorders 
x Endocrine abnormalities 
o Hypothyroidism 
o Hypogonadism
Medications 
x Opioids 
x Hypnotics 
x Anxiolytics 
x Antiemetics 
Direct effects of cancer and 
tumour burden 
Fig 3 
(Modified figure 115)
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The literature presents several figures and tables with lists of possible etiologic explanations 
to fatigue. The problems with these lists are multiple: Several of the factors and conditions are 
non specific factors and conditions which “always“ will be accompanied with fatigue, such as 
sepsis, and dehydration. These factors are not specific for cancer related fatigue. The lists do 
not differ between acute and chronic fatigue, and acute fatigue will usually be relieved by 
successful treatment of the condition responsible (ie sepsis). The causes to chronic fatigue in 
cancer patients are seldom explored, and it is probably a more complex phenomenon hardly 
possible to explain by single factors. The hypothesis of the etiology of fatigue can 
alternatively be presented as models. 
Models of fatigue in cancer  
Some models of fatigue in cancer have been presented during the last decades. Piper et al 
developed one of the first integrated models of fatigue in cancer which explained the 
multidimensional and complex nature of fatigue, including biochemical, behavioural, social 
and psychological influence.116 The model by Nail and Winningham stress the role of other 
symptom of cancer and their influence on developing fatigue.117 They explain that symptoms 
such as pain, nausea or immobility might lead to inactivity, promoting the development of 
secondary fatigue. Further research have supported the hypothesis of secondary fatigue, 
describing a vicious circle, leading to activity/rest imbalance: unusual tiredness (fatigue) leads 
to increased need for rest, leading to activity intolerance, to weakness, to reduced physical 
performance, and finally again to increased fatigue.118 These models again lack a critical 
evaluation of which pathophysiological factors that may play a role. The models do not 
recognize possible biological variables that may be relevant for fatigue. 
Cytokines 
The role of cytokines in cancer-related fatigue is incidentally discussed by several 
researchers.102, 119-122 Both cancer and its treatment by chemotherapy, radiotherapy and 
surgery elevate the levels of the pro-inflammatory cytokine TNF and of IL-1 and IL-6, which 
are products in a cytokine cascade. Cytokines are protein-signalling molecules with specific 
receptors and complex biological effects. They can be produced by many cell types including 
fibroblast, neurons, astrocytes, macrophages, tumours and epithelial cells of various types. 
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The biochemical and clinical effects are complex and are mediated by a number of signalling 
pathways.102
The hypothesis that cytokines may play a role in cancer-related fatigue is consistent with 
various clinical studies and observations. One of the first article indicating that cytokines was 
associated with cancer-related fatigue was published in 1993.123 The authors demonstrated an 
increase in interleukin-1B (IL-1) during radiotherapy parallel to an increase in fatigue. Several 
researchers have found elevated levels of cytokines in patients reporting chronic fatigue. Later 
empirical studies have failed to demonstrate significant associations between various 
cytokines and fatigue.124, 125 Still, there is growing evidence that cytokines both 
experimentally and clinically are messengers that trigger manifestations of disease such as 
fever, cachexia and anemia as well as several symptoms including fatigue, all commonly 
associated with cancer.122 Cytokines can alter brain functions, and the research on the effects 
of cytokines on disease manifestations is rapidly growing.121, 126 Cytokines may also play a 
role in sleep regulation, which may be of particular relevance for fatigue.127 There are also 
indications that cytokines are the mediators of sickness behaviour.128 In sum, the results of 
various studies of cytokines indicate they may have psychobiological effects which may cause 
fatigue.
Anemia
Anemia is also frequently discussed as a cause to fatigue. Blunted endogenous erythropoietin 
response, cytokines induced erythropoiesis suppression (IL-1, IL-2, IL-6 and TNF that 
suppress red blood cell production), functional iron deficiency (even when their iron levels 
appear normal), and finally chemotherapy-induced bone marrow suppression, bone-marrow 
infiltration and bleeding are possible etiologic factors of mechanisms behind cancer related 
anemia.122 Several studies have demonstrated that anemic cancer patients are more fatigued 
than non anemic cancer patients, and that treatment of anemia can result in less fatigue and 
improved quality of life.129-133 The findings concerning the effects of haemoglobin level upon 
fatigue is however conflicting. Lind et al reported that only 8 % of the variation in fatigue 
scores in cancer patients could be explained by anemia.132 In a study of fatigue in elderly 
cancer patients above 60 years, a statistically significant but weak correlation was found 
between fatigue severity and anemia (r=-0.30, p<0.01).134 Furthermore, a prospective 
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controlled study of palliative patients failed to demonstrate any effect of haemoglobin level 
upon fatigue,135 and the effects of correction of anemiae upon fatigue are also disputed.136
Anaemia is not as common in cancer patients treated with radiotherapy although such patients 
typically report more fatigue than chemotherapy patients. Furthermore, several studies have 
reported an increase in “energy” or QoL in patients with anaemia being treated with 
recombinant human erythropoietin alpha (rHuEPO), but the precise relationship between 
fatigue and measures of “energy” and QoL remains to be identified.102, 130, 137 In most of the 
studies a variety of outcomes have been used, which hampers the interpretation of the 
findings.
Psychological disorders and sleep disturbances
Psychological factors have been suggested in some studies to be associated with cancer-
related fatigue.125, 138, 139 but the results have been contradictory, and a causal relationship has 
not been demonstrated.140 A strong correlation between the intensity of fatigue and 
psychological disorders such as depression was found in cancer patients.141 In contrast, Visser 
et al reported only a modest correlation between fatigue and depression in cancer patients 
undergoing radiotherapy.92 The relationship between fatigue and depression is clearly 
complex in that fatigue is one of the nine criteria for depression according to the DSM-IV,91 but 
not necessary indicated depression, and may also be a consequence of being depressed. 
Sleep disturbance are common in cancer patients, but few studies have addressed this.142
There are different types of sleep disorders, which are all accompanied by fatigue. These 
include insomnia, hypersomnia, narcolepsy, and obstructive sleep apnoea and circadian 
rhythm sleep disorders. Insomnia and hypersomnia have been found to be prevalent and 
evidence is accumulating on the prevalence of sleep disorders in cancer patients.143 Although 
not fully explored, cancer treatments including opioids also alter the circadian rhythm. A 
recent study demonstrated that fatigue, mood and depression were significantly associated 
with concurrent changes in circadian rhythm.144 Fatigue during radiotherapy was best 
explained by the pre-treatment level of fatigue, which was highly related to sleep disturbance 
145 whereas in another study increased sleep requirement and radiation induced fatigue were 
associated to a systemic reaction of increased inflammatory cytokine interleukin-1.123
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Possible etiology to fatigue in non-cancer patients  
Fatigue is a cardinal symptom of MS and systemic lupus erythematosus, and the severity of 
the symptom will often reflect disease activity.68, 146, 147 Studies have demonstrated a 
correlation between fatigue and increased circulation immune activation.127, 148 Medications 
such as interferon-Į and – ȕ produce prominent fatigue as an adverse effect. 149 Analogous, 
fatigue is reported to be associated with the systemic effects of the immune activation in 
patients with chronic heart failure.150, 151
In patients with chronic lung diseases, the mechanism to fatigue is not completely clear. 
Fatigue is additionally to dyspnoea the two most common symptoms in patients with chronic 
obstructive pulmonary disease (COPD). Clinical experience and studies have demonstrated 
that the two symptoms are highly correlated in COPD patients, perhaps because the 
mechanism are unclear and likely overlap.152 The decline in cognitive function indicating 
symptoms of mental fatigue observed in COPD patients are proposed to be related to a 
decrease in oxygen transport to the brain.153 Arterial oxygen desaturation in these patients 
may develop as result of their disease.154 Pulmonary abnormalities results in arterial oxygen 
desaturation with resultant dyspnoea during activity, which again result in avoidance of 
activity and further deconditioning.153 Reports of positive relationship between exercise 
related improved oxygen use and improved fatigue/dyspnoea, and between aerobic exercise 
and cognitive function support this assumption.152, 153
Fatigue is also related to disturbances in the hypothalamic-pituitary-adrenal axis (HPA).155, 156
In diseases or conditions related to an underactive HPA-axis, fatigue may be caused by the 
proinflammatory cytokines that become activated by reduces corticotropin releasing factor 
and low cortisone concentration.153, 156 Disturbance in the HPA axis and low level of cortisone 
have been reported in some studies of sufferers of chronic fatigue syndrome.157 Development 
of sudden and profound chronic fatigue in physically active and highly motivated 
sportspeople (overtrained athlete syndrome) is also affected by hypothalamic and related 
neuroendocrine changes.158
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Possible etiology of fatigue in cancer survivors 
In 1987 Devlen et al performed a prospective study of the psychological and social morbidity 
following the diagnoses and treatment of HD and NHL.159, 160 Frequent complaints of 
tiredness (32%), loss of energy (43%), poor concentration (15%) and memory impairment 
(19%) were found. Although the authors found that these symptoms were associated with 
increasing age, anxiety and depression, they also suggested that these represented minor 
cerebral damage due to central effects of chemotherapy or viral infection during periods of 
immunosuppression.160 In the same study, it was also emphasized the use of magnetic 
resonance imaging (MRI) as a sensitive method to gain objective evidence of cerebral 
damage.161 In children with neurological and neuropsychological treatment related sequelae, 
MRI have demonstrated white matter changes and periventricular/subcortical changes even in 
patients with mild symptoms not uncovered by other neurological means of investigation.161
These hypotheses have not been investigated in studies of fatigue in HDS later. In non cancer 
patients, however, studies have demonstrated an association between fatigue and similar MRI 
findings.162-165
Greenberg et al was one of the first to report an association between fatigue and cytokines due 
to the ability of proinflammatory cytokines to signal the central nervous system to induce 
symptoms of fatigue and other “sickness behaviour “.123 The hypothesis that inflammatory 
alterations underlie chronic fatigue in cancer survivors is of special relevans in the study of 
fatigue in HDS due to the biological components of HD. The cytokine hypothesis and 
dysregulation in the HPA-axis is also the underlying theory in several of the recent and 
ongoing studies of chronic fatigue in breast cancer survivors.166-168
The few studies of long term cancer survivors conducted until now have also suggested that 
chronic fatigue may be related to late effects of treatment.69, 107, 113 In 1996 a Norwegian study 
demonstrated that patients treated with mantle field irradiation had higher risk of dyspnoea 
leading to higher fatigue score and lower quality of life.169 Lund et at could in her thesis 
demonstrate cardiopulmonary sequelae in more than half of otherwise healthy long term HDS 
which all had been treated with radiotherapy alone or in combination with chemotherapy.170
Later studies of the same patient cohort demonstrated a 2-3 fold increased level of chronic 
fatigue as compared to norms from the general population.4 Taking into consideration 
observations of fatigue in non cancer patients with cardiac and pulmonary diseases, it is 
reasonable to question whether chronic fatigue in HDS represents symptoms of late somatic 
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complications after cancer treatment. This research question has not been investigated in 
studies earlier. Consistent with this, specific research on the role of endocrine late effects such 
as hypothyreosis and gonadal dysfunction in the etiology of fatigue in HDS have not been 
performed. 
A critical moment for an accurate understanding of chronic fatigue in cancer survivors is the 
knowledge about fatigue before treatment and ideally during the treatment period. In the only 
prospective report on fatigue in HDS, Ganz et al demonstrated that fatigue was a substantial 
problem in patients with HD before treatment and did not decrease after ending treatment.113
As discussed in the paper, this may indicate that fatigue is related to inflammatory processes 
caused by the underlying disease or by effects of the treatment.113 Hjermstad et al described 
prospectively the trajectory of fatigue and other HRQoL domains including anxiety and 
depression in lymphoma and leukaemia patients before, during and 1 year after HDC and 
ASCT/SCT.171 The lymphoma patients reported more fatigue and other symptoms and worse 
function on most of the HRQoL domains before and 1 year after treatment as compared to the 
leukaemia patients. If this pattern persists in an extended follow study above 1 year after 
treatment, the observation will support the postulation that fatigue in lymphoma patients is 
related to the disease itself or to certain effects of the disease or the treatment given. 
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Aims of the study
The overall aim of this thesis is to increase the understanding of fatigue. The focus is 
on the frequency, the assessment methodology and the etiology of the phenomenon.  
x Methodological issues in assessment of fatigue in patients with advanced 
disease as well as in cancer survivors are addressed in Paper I, and the 
research questions were as follows:
o Does the EORTC QLQ-C30 fatigue scale measure mainly physical 
fatigue?  
o Does the EORTC QLQ-C30 fatigue scale demonstrate a poorer 
sensitivity in measuring fatigue as compared to the domain specific 
Fatigue Questionnaire?
x Prospective design with follow up extending at least one year post treatment is 
probably the best method of assessing fluctuations and symptom burden 
during and after cancer treatment. Paper II address subjective health in patients 
with hematooncologial malignancy during and until 3-5 years after high dose 
chemotherapy and stem cell transplantation with specific focus on fatigue. 
Based on clinical experience and previous work two main research questions 
were raised: 
o Do lymphoma patients 3-5 years after transplant report lower function, 
more symptomatology and poorer overall quality of life as compared to 
leukemia patients after transplant? 
o Do lymphoma patients report more fatigue 3-5 years after transplant as 
compared to leukaemia patients and compared to general population? 
x Fatigue is a multidimensional and multifactorial phenomenon. The 
pathophysiological mechanisms involved are not well understood. In order to 
improve the understanding of etiological factors the following research 
questions were raised, and these are adressed in paper III – V:
o What is the explanatory value of cardiac, pulmonary and endocrine 
complications on fatigue in HDS? 
o Is fatigue in HDS related to abnormalities in central nervous system or 
alterations in the immune system, and what are the possible causes? 
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Material and Methods 
Study population and design 
Five different cohorts are included in this thesis. A series of different outcomes in 
addition to fatigue were used in the various cohorts. Table 4 gives an overview of the 
populations, primary and secondary outcome as well as the study designs. 
Furthermore the links between the cohorts and the various papers are briefly given. 
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Study populations 
1. Palliative cancer patients with bone metastases 
Patients with advanced cancer and painful bone metastases were recruited in the period from 
1998-2000, to participate in a randomised clinical trial comparing the effect of standard 
radiotherapy versus hypofractioned radiotherapy. The cancer diagnoses were mixed, with the 
majority suffering from breast and prostate cancer. The patients should have bone metastasis 
verified by mean of x-ray, bone scan, computer tomography (CT) or MRI. There were no 
limitations with the site of the bone metastases. The patients should have a Karnofsky 
Performance status equal to or above 40, and the bone metastases should result in clinically 
important pain judged by the physician and the patient. The first 249 randomized patients 
were included in the present study (Paper I). Patients completed the EORTC QLQ-C30 and 
the Fatigue Questionnaire (FQ) at study entry and thereafter every month for 6 months (28 
weeks) or until death. The assessments at study entry (T0) and after 12 weeks (T12) and 28 
weeks (T28) were used in the present analysis. In Paper I, an additional cohort was included; 
Patients with leukaemia and malignant lymphoma curatively treated with stem cell 
transplantation and high dose chemotherapy (cohort 2, n=128). 
2. Leukaemia/Non-Hodgkin/Hodgkin´s Disease, high dose chemotherapy 1993-1996 
In a three years period from 1993 to 1996 all consecutive leukaemia patients admitted for high 
dose chemotherapy (HDC) followed by allogeneic bone marrow or blood stem cell 
transplantation (SCT) at the National Hospital (NH) were invited to participate. All 
consecutive patients with HD or NHL treated with HDC and reinfusion of autologous bone 
marrow or blood stem cells (ASCT) at the Norwegian Radium Hospital (NRH) were also 
included. At the same time, all patients who were admitted to the NRH for diagnostic 
verification of HD or NHL, and start of standard treatment, were invited to participate in the 
study as a comparison group. The recruitment of patients and participating rates is described 
elsewhere.172
Of the 76 SCT patients, 85 ASCT patients and 161 CT patients who were initially 
approached, the baseline questionnaires at the time of study entry were completed by 62, 69 
and 123 patients respectively. One SCT patient and five CT patients were excluded from the 
analyses because only the first questionnaire was filled in due to critical illness and death. 
Over the years of follow-up, 16 SCT patients, 14 ASCT patients and 20 CT patients died, 
while 10, 15 and 27 patients respectively withdrew. Due to practical reasons, the last 
evaluation at least 3 years post transplant was performed as a cross-sectional assessment. The 
EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS) and the FQ were 
mailed to the 141 eligible patients (SCT, n = 38) or autologous stem cell transplantation 
(ASCT, n = 42) (CT, n=61). The response-rates at the last assessment were 92%, 95% and 
87% respectively (Figure 4a-c).
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Figure 4a.
Attrition of patients from approach to minimum 3 years of follow up. 
SCT group 
Missing²: 5³ 
Died: 1, missing²: 4 
Died: 2, no answer4: 1, 
missing²: 1 
2 months post-SCT: 55 (n=57)
Died: 1, no answer4: 1 
4 months post-SCT: 45 (n=55)
Died: 5, no answer4: 3, 
missing²: 2 
6 months post-SCT: 44 (n=47) 
Died: 2, no answer4: 1 
8 months post-SCT: 43 (n=44)
Died: 1 
1 month post-SCT: 56 (n=60)
Died:1, no answer4: 1 
1 month pre-SCT: 56 (n=61)
2 weeks post-SCT: 56 (n=61)
Baseline: 61
12 months post-SCT: 41 (n=43)
Approached: 76
Did not proceed to SCT: 8 
Treated abroad: 2 
Declined participation: 4 
Omitted from analyses¹: 1 
+ 36 months post-SCT: 35 (n= 41)
Died:3, no answer4: 3 
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Figure 4b. ASCT group. 
Missing²: 10³
Died: 1, missing²: 4
No answer4: 1, missing²: 2
2 months post-ASCT: 59 (n=67)
No answer4: 4, missing²: 4
4 months post-ASCT: 55 (n=63)
Died: 1, no answer4: 4,
missing²: 3
6 months post-ASCT: 53 (n=58)
Died: 2, no answer4: 1
missing²: 2
Died: 1, no answer4: 2
missing²: 1
Died: 9, no answer4: 2
1 month post-ASCT: 65 (n=68)
No answer4: 1
1 month pre-ASCT: 59 (n=69)
2 weeks post-ASCT: 64 (n=69)
Baseline: 69
12 months post-ASCT: 51 (n=52)
8 months post-ASCT: 51 (n=55)
Approached: 85
Did not proceed to
ASCT: 11
Declined
participation: 5
+ 36 months post-ASCT: 40 (n=51)
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Figure 4c. CT group. 
Missing²: 3
No answer4: 5, missing²: 3
ASCT5: 1
Died: 1, no answer4: 3,
missing²: 1, ASCT5: 2
6 months: 98 (n=106)
Died: 2, no answer4: 3,
missing²: 3
8 months: 94 (n=101)
Died: 3, no answer4: 3,
ASCT5: 1
12 months: 85 (n=94)
Died: 3, no answer4: 5,
ASCT5: 1
4 months: 105 (n=112)
1 month: 115 (n=118)
2 months: 109 (n=118)
Baseline: 118
Approached: 161
Ineligible6: 38
Omitted from analyses¹: 5
+ 36 months: 53 (n=85)
Died: 11, no
answer4:8, ASCT5: 13
¹ patients who filled in the first questionnaire only 
² patients who failed to fill in a single questionnaire, but who wanted to remain in the study 
³ because inclusion was less than one  month prior to transplant, questionnaires were not administered 
to five SCT and nine ASCT patients 
4 patients who failed to respond after one reminder or who declined further participation on the 
provided statement coupons: withdrawn from the sample 
5 accepted onto the ASCT programme due to relapse or disease progression 
52
6 due to: benign disease (1), no treatment (3), radiotherapy only (20), low intensive treatment with 
Chlorambucil and Prednison (14) 
3. Non-Hodgkin/Hodgkin´s Disease, high dose chemotherapy 1987-1993 
From 1987 until ultimo 1993 all 85 cases of malignant lymphomas requiring autologous bone 
marrow transplantation (ABMT) in Norway were treated at the NRH. In January 1997 46 
patients were alive, in complete remission (CR) and invited by mail to participate in this 
study. In order to assess late side effects after ABMT, patients with a follow up of three years 
or more were approached. One refused to see a new doctor, another answered too late for 
inclusion, one had moved abroad, and four patients did not answer to the request. This led to 
39 patients, and 38 patients of these completed the mailed questionnaires, the EORTC QLQ-
C30 and FQ. Before the clinical work up, three patients declined to participate due to 
hospitalization because of cerebral insult, myelodysplastic syndrome or major psychiatric 
problems. Two of the blood samples were damaged during transportation, thus 33 serum 
samples were valid for use. These 33 patients comprised the material in Paper III.  
4. Hodgkin´s Disease Survivors, Norwegian Radium Hospital, 1980-1988 
All living patients treated for HD at the NRH in the period between 1971 and 1991, 15 to 61 
years of age at the time of diagnosis, and 74 years or less by the end of 1993 were invited to 
participate in a cross- sectional follow-up study of subjective health. In 1994, 559 HDS 
received a mailed questionnaire, and 459 patients (82%) responded.4 A subcohort of these 
subjects, limited to patients who had been treated between 1980 and 1988 with standardized 
mediastinal radiotherapy alone or in combination with chemotherapy, were included in a 
second study in order to assess long term cardiac and pulmonary complications. Thyroid status 
was also assessed. Patients aged 50 years or younger at the time of diagnosis and who had 
been in complete remission for more than 5 years at the time of follow-up were invited to 
participate. In the study, 116 of 129 eligible patients were included (90%).41, 170, 173
In Paper IV we included all the patients who participated in both of the above mentioned 
studies (n=92).
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5. Hodgkin´s Disease Survivors, Trondheim University Hospital, 1987-1997 
Starting in 1987, all patients with HD living in middle part of Norway were treated at the 
Trondheim University Hospital. Sixty-two patients was treated in the period from 1987-1997, 
alive without evidence of active disease in 1999 and aged from 19 to 74 years. These were 
eligible for a follow-up study. A questionnaire was mailed to all the patients. One written 
reminder was mailed to the non-responders. Fifty-three patients (86%) returned the 
questionnaires. All patients with chronic fatigue (fatigue cases; n=18) were invited to a clinical 
examination and a cerebral MRI. Fifteen patients agreed to participate. Consequently 13 
patients completed the examinations. Additionally, 14 aged-and gender matched HDS without 
fatigue was used as a comparison group yielding a total number of 27 patients participating in 
the study presented in Paper V. 
Reference populations 
1. Population data on Fatigue Questionnaire 
The reference data on FQ is achieved from a population survey among the general Norwegian 
Population conducted in 1996.83 A representative sample of 3500 Norwegian citizens, aged 
19-80, randomly drawn from The National Register by the Norwegian Government Computer 
Centre (SDS), were mailed a questionnaire package. The package included FQ, items on 
sociodemgraphic variables and health variables. A total of 2323 (67%) people responded, and 
2185 completed the questionnaires. Data from the population sample with the same age range 
as the patients included in the respective studies in this thesis were included as respective 
reference values.  
2. Population data on EORTC QLQ-C30 
A sample of 3000 people representative of the adult (above 18 years) Norwegian population 
was randomly drawn from The Office of the National Register. All participants received a 
mailed questionnaire package consisting of EORTC QLQ-C30, and form that covered 
sociodemographic data. A total of 1965 people completed the questionnaires, yielding a 
responsrate of 68%. Details to the survey is described elsewhere.174 The results of this survey 
constitute the reference value on HRQoL from the general population, divided by age and 
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gender. Data from the population sample that were in the same age range as the patients 
included the respective studies were included as reference data in the different studies. 
Design
This thesis constitutes three different types of studies: 
1. Methodological study validating fatigue instruments (Paper I).  
2. A prospective study with serial measurement of subjective health before, during and up to 
3-5 years follows up (Paper II). 
3. Cross sectional studies investigating possible etiology of fatigue (Paper III; IV; V). 
1. The methodological study 
In this study a fatigue scale in a HRQoL instrument, the EORTC QLQ-C30 fatigue scale, and 
a fatigue specific instrument, the FQ, were compared (Paper I). Two cohorts of patients, a 
cohort of patients with advanced metastatic cancer and a cohort of cancer survivors, were 
chosen in order to test the validity of EORTC QLQ-C30 fatigue scale in different types of 
patients with different symptom burden. Details to patient cohorts included are described 
elsewhere in the thesis. Patients who had completed both questionnaires according to the 
respective protocols were included. The patients with advanced cancer were included in a 
prospective study of HRQoL after palliative radiotherapy. Data at baseline, 12 and 28 weeks 
after intervention were used in the present work. This gives possibility to evaluate changes in 
symptom levels as the disease develops. The cancer survivors were originally included in a 
prospective study with the purpose to assess HRQoL, fatigue and psychological distress 
before, during and 3-5 years after stem cell transplant and high dose chemotherapy. In this 
work data from the assessment 3-5 years post treatment were included.  
2. The prospective study  
The prospective study was an extended follow up study of patients with leukemia or 
lymphoma treated with HDC and SCT/ASCT (SCT/ASCT patients respectively) or standard 
chemotherapy (CT patients) (Paper II). The patients were approached and completed the first 
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questionnaire prior to the transplant or start of standard treatment. Medical data were 
collected from the patients’ records. 
A questionnaire package was mailed to the transplant patients eight times and to the CT 
patients six times until one year after the transplant or start of chemotherapy. The last 
questionnaire package was sent to the patients as a cross sectional assessment 3-5 years after 
transplant or start of chemotherapy. At the last assessment, the FQ were added to the 
questionnaire package. Non responders received new questionnaires as a reminder after two 
weeks, including a statement coupon for indication of the reasons for withdrawal. The 
timeline for the assessment is presented in table 6. 
Table 6. Administration of questionnaires in the prospective study
Assessment 
(months)
Baseline 1 month 
pretrans-
plant
2
weeks
1
month
2
months
4
months 
6
months
8
months 
1
year
3-5 
years 
Interview All All
EORTC All SCT/
ASCT
SCT/
ASCT
All All All All All All All
HADS All SCT/
ASCT
SCT/
ASCT
All All All All All All All
FQ All 
Karnofsky 
WHO
SCT/
ASCT
SCT/
ASCT
SCT/ 
ASCT
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For practical reason the last assessment was performed as a cross-sectional assessment 3-5 
years after transplant or start of chemotherapy. Ideally, we should have completed the 
longitudinal design with individual assessment 3 alternative 5 years after treatment.  
In this study we assessed fatigue prospectively during the first year by EORTC QLQ-C30 fatigue 
scale. At the last assessment the FQ measuring physical and mental fatigue was administered to 
the patients. We would like to have baseline and prospectively assessed data from FQ. As this 
study was planned (1993), no Norwegian version of FQ existed, therefore we do not have 
prospectively data of FQ in this study. 
3. Cross sectional studies 
A cross sectional design was used in order to explore possible mechanism to fatigue. More 
specific, we wanted to explore to what extent fatigue can be explained by biological variables 
possibly related to the primary malignancy and/or treatment (Paper III, IV, and V). 
Additionally to self-report questionnaires, objective examinations of certain organ systems 
were performed, and possible associations between subjective and objective health outcomes 
were explored. Details to outcomes and methods are described in the results part of the thesis. 
The patient populations were previously treated for HD or NHL with a mean observation time 
since diagnosis of at least 6 years. Despite that we in only two of the studies defined a 
minimum time in complete remission of at least three years, the majority of the patients have 
had at least five years disease free survival indicating that they were cured of the malignant 
disease.
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Methods 
Patients self report questionnaires 
Fatigue is measured by the Fatigue Questionnaire (FQ) and the fatigue subscale within the 
EORTC QLQ-C30. In consistency with the defined aims and hypothesis, HRQoL and 
psychological distress were additionally defined outcomes, and was measured in combination 
with the FQ in three of the five papers as listed in table 5.
Copies of all questionnaires are provided in the Appendix section at the end of the 
dissertation.
Fatigue Questionnaire 
The Fatigue Questionnaire (FQ) was originally developed for assessing fatigue in patients 
with Chronic Fatigue Syndrome (CFS),175 and was later refined in a validation study in which 
all items specifically related to CFS were removed.78 It has good face validity and reasonable 
discriminant validity. It is found to be sensitive to change and allowed for detection of fatigue 
cases in epidemiological studies. In recent years it is employed in several studies in cancer 
populations.4, 111, 135, 176 The FQ is translated into Norwegian, and Norwegian population 
norms have been published.83
FQ is a two-dimensional instrument, consisting of 11 items measuring physical fatigue (PF; 7 
items) and mental fatigue (MF; 4 items) in two separate subscales. PF corresponds to the 
subjective feeling of being exhausted, lacking energy and less muscle strength. MF addresses 
the subjective experience of being mentally exhausted, and the items encompass 
concentration, memory and speech. Two additional items ask for the duration and extent of 
fatigue. The total sum of both subscales is designated total fatigue. Two scoring systems are 
employed. Likert scoring (0,1,2,3) is used for the construction of the sum scores for the 
subscales and the whole scale respectively. A higher score implies more fatigue. The 
dichotomised scoring (0,0,1,1) is only used for the case-definition. Based on the validation 
study, a case refers to a total dichotomised score of 4 or higher and duration 6 months or 
longer.74, 78 The two factor structure was confirmed in the validation study (Paper I). 
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By missing data in four or fewer items, the missing value was replaced with the means of the 
corresponding known variable values from each sample. 
EORTC QLQ-C30 
EORTC QLQ-C30 is a health related quality of life questionnaire developed primarily for use 
in cancer patients.62 The 30-item questionnaire is composed of scales that evaluate physical (5 
items), emotional (4 items), cognitive (2 items), role (2 items) and social (2 items) function as 
well as general well being. Higher scores indicate better functioning. Three symptoms scales 
evaluate fatigue (3 items), pain (2 items) and nausea and vomiting (2 items), and 6 single 
items measure financial impact and various physical symptoms. Higher scores on these scales 
and items indicate more symptoms. Before statistical analyses are made, the raw scores are 
linearly transformed to a 0-100-point scale.177
Missing items were imputed according to the method advocated by the EORTC Quality of 
Life Study Group.177 If at least half of the items from the scale were completed, the values of 
the missing ones were imputed as the mean value of the completed items. 
Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) is widely used for assessment of 
psychological distress in cancer patients.178, 179 The Norwegian version of HADS was released 
in 1988. It contains 14 items, measuring anxiety (7 items) and depression (7 items) in two 
separate subscales. The responses are scored 0,1,2,3. The total score of each scale is derived 
by simple addition, and a higher score implies more distress. For anxiety and depression case 
detection, two cut-offs is recommended by the authors;178 a mean score of eight to ten is 
defined as a probable case, and 11 or higher is defined as a definite case. The lower threshold 
was used in this study for the detection of possible cases. 
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Observer rated scale 
Karnofsky Performance Status Scale 
The Karnofsky Performance Status (KPS) scale is an observer rated scale, which is frequently 
referred to as a proxy measure of HRQoL in clinical trials. It has been used in validation 
studies of HRQoL measures.62 The scale only measures physical function as one dimension of 
the HRQoL concept. It contains 11 categories ranging from normal performance (100%) to 
death (0%). 
Clinical procedures 
Laboratory analysis 
Blood serum diagnostics were performed in the clinical studies described in paper III-IV.  
Hormone analyses 
Laboratory tests of serum levels of thyroxin stimulating hormone (TSH) and thyroxin 
hormone (FT4), follicle stimulating hormone (FSH), lutein hormone (LH), estradiol and 
testosterone was performed according to standard procedures. The thyroid and gonad function 
was classified according to standard values of the serum hormone levels as described in the 
papers.
Cytokine analyses 
In Paper III, interleukin 6 (IL-6), tumour necrosis factor (TNF), and soluble TNF-p55 and p75 
receptors were determined in serum samples from blood drawn into sterile vacuum tubes 
without additives. Tubes were immediately immersed in melting ice, and serum samples were 
stored at –70°C in multiple aliquots until analysis.  
IL-6
IL-6 dependent mouse hybridoma cell line B13.29 clone B9 determined IL-6.180 Serial 
dilutions of serum samples were incubated for 72 hours with IL-6 dependent cells. Viability 
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was measured in calometric assay with the MTT tetrazolium salt (Sigma Chemical Co, St. 
Louis, Missouri, USA).181 Recombinant IL-6 was included as a standard. 
TNF
TNF was determined by its cytotoxic effects on the fibrosarcoma cell line WEHI 164 clone. 
182 Recombinant TNF was included as a standard. 
Soluble TNF-receptors (sTNFR) 
The TNF receptor p55 and p75 were analysed by immunoassay.183 Immunoplates were coated 
with the monoclonal antibodies IV4E and 3H5, recognizing non-TNF binding sites of p55 and 
p75 TNFR, respectively. Recombinant human p55 and p75 (provided by Dr. Loetscher, F. 
Hoffmann-LaRoche, Basel, Switzerland) served as standard. Measurement of soluble TNF 
(sTNF) receptors bears some advantage compared to direct quantification of TNF. sTNF 
receptors are very stable, can be determined in stored sera, and allow some insight into TNF 
biology. Both receptors sTNFp55 and p75, as well as TNF are found to be elevated in cancer 
patients.184, 185
Immunological analysis of cerebrospinal fluid and serum (paper V) 
In Paper V we performed immunological analysis of serum and cerebrospinal fluid of the 
patients with pathological brain MRI lesions.  
Immunological analysis of cerebrospinal fluid 
Spinal punctures were performed at L3-L4 or L2-L3 vertebral spaces using a 25G spinal 
needle. The spinal fluid was examined for cells, protein and glucose concentration. Protein 
electrophoresis was performed to analyse immunoglobulines. IgG isoelectric focusing was 
performed in order to improve the exposal of oligoclonale bands. An extended screening 
included anticardiolipin antibody IgG/IgM (diagnostic of systemic lupus erytematosus), 
concentration of lyzozymes and ACE (diagnostic of sarcoidosis of the central nervous 
system), and serologic analysis of Lues, Hepatitis B and Borrelia.
61
Immunological analysis of serum
Blood serum diagnostics were performed including analyses of glucosis, kobalamin and 
protein (protein electrophoresis with IgG isolecetric focusing). An extended screening 
included antinucelar antibodies (ANA), neutrophil cytoplasma antibody (c-ANCA (proteinase 
3 / p-ANCA (myeloperoksidase)), anticardiolipin antibody IgG/IgM, serum concentration of 
lyzozymes and ACE, cryoglobulin, and serologic analysis of Lues, Hepatitis B and Borrelia.
Assessment of cardiopulmonary function 
Evaluation of the cardiopulmonary function and possible relation to fatigue is described in 
paper IV. The assessment of cardiopulmonary function was performed at the Department of 
Thoracic Medicine and Medical Department, the National Hospital, University of Oslo in the 
frame of the doctoral thesis by Mai Brit Lund.170 In the following a description of the 
procedures is given in accordance to the thesis by Lund. 170
Assessment of pulmonary function 
All measurements were performed with the Gould automated system 2400 (Sensormedics 
BV, Bilthoven, Netherlands). It is a computerized pulmonary function unit that provides 
following test capabilities: spirometry, lung subdivisions, and lung volume determination by 
the multibreath Helium equilibration method, and single breath diffusing capacity.  
Measurements of ventilatory function 
The measurements of ventilatory function included measurement of static lung volum by the 
multibreath helium equilibration method, and dynamic spirometry.  
Measurements of gas diffusing capacity (TLCO) 
The transfer factor for the lung for CO (TLCO) was measured by the single breath technique. 
The alveolar volume (VA) was calculated by the helium dilation method during the same 
manoeuvre. In all subjects the measured TLCO-values were also adjusted for the Hb-
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concentrations obtained at the same day as the lung function testing. For the Hb-correction, 
the method of Cotes et al.186 was used, which has been the method recommended by both the 
American Thoracic Society (ATC) and the European Respiratory Society (ERS).187, 188 In the 
follow up study of HDS there was practically no difference between the measured and the Hb-
adjusted TLCO values. The majority of the subjects were non-anaemic adults, and only in few 
cases did the Hb-adjusted TLCO values differ significantly for the measured values. 
Reference values 
Reference equations provide a context for evaluating the pulmonary function values of an 
individual subject or a study population in comparison to the distribution of measurements in 
a reference population.170 The reference population and the study population should comprise 
of subjects with similar characteristics for the variables that affect lung function (sex, age, 
height, race). Additionally, specific methodological, epidemiological and statistical criteria 
should be fulfilled when selecting the reference values.189 In the follow up study of HDS the 
reference values recommended by the ERS were applied 188, 190.
It is a common practice to express the results of pulmonary function testing as percent 
predicted, i.e values observed/value predicted x100, and to regard 80% of predicted as the 
lower limit of normal. In the study by Lund et al 80% of the predicted corresponded to the 
lower 5% percentile of the summary equations for lung volumes and TLCO in the reference 
materials recommended by the ERS.170
Radiographic evaluation 
Chest radiographs in standard anteroposterior and left lateral projections were included in the 
assessment of pulmonary complications in the follow up study of HDS described in paper IV. 
The HDS included in the study had all received high-voltage chest radiation. Upper and 
medial parts of their lungs had been exposed to the entire radiation dose of 40-42 Gy, while 
the rest of the lung tissue had received scattered radiation or radiation transmitted through the 
lung shielding. It was therefore assumed that a proportion of the patients had developed 
various degrees of radiation fibrosis.170
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The occurrence and degree of radiation fibrosis was described according to the method 
described by Jensen.191 It is the only existing standardized and validated method for 
systematic radiographic evaluation of pulmonary fibrosis after mantle field radiation. 
According to this method, fibrosis was classified as “none”, slight”, “moderate”, or “severe” 
based upon a scoring system of the fibrotic manifestations. The radiographs were graded in 
blinded manner by two independent observers. In case of discrepancy, the radiographs were 
re-evaluated by the two observers jointly and an agreement was reached. 
Assessment of cardiac function 
Echocardiography
Transthoracic ultrasonic measurements were obtained by Vingmed CFM 700 or 750 cardiac 
ultrasound machine (Vingmed Sound, Horten, Norway) with a Duplex mechanical annual 
array probe. The probe applied the frequency 3.25 MHz for imaging tissue and 2.5 MHz for 
Doppler recordings.170
The subjects were examined in the lateral recumbent position after 15 minutes of rest. The 
heart was visualized using standard ultrasonic techniques and acoustic windows. M-mode 
echocardiography, two-dimensional technique and Doppler recordings determined cardiac 
dimensions and blood flow. Pulsed, continuous and colour Doppler echocardiography in at 
least three planes were used for exploring heart valve function. Two well-trained technicians 
did all the echocardiographic examinations, and the recordings were supervised and 
interpreted by the same senior cardiologist. However, as the observers were not blinded, some 
degree of observer bias cannot be excluded. 
Exercise testing 
The HDS included in the study described in Paper IV performed an exercise test. A stationary, 
electrically braked cycle ergometer (ErgoMetrics 900, Jaeger) was used. The initial workload 
was 50 watt, and increments of 50 watt were subsequently added every 4 minutes until 
exhaustion (defined as inability to pedal at 60 rev/min). The patients were monitored 
continuously by standard 12-lead ECG, and tracings were recorded at the end of each exercise 
step and every 2 minutes during the post-exercise recovery phase (minimum 5 minutes). A 
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pulse oximeter with a flexible finger probe (Minolta Pulsox-7, Devillbiss) was used for 
continuous monitoring of oxygen saturation.170
The major reason for the principal investigators for applying exercise test was to detect 
coronary artery disease, which is reported in patients previously treated with mediastinal 
radiation.192-195 In non-malignant patients with coronary heart disease and heart insufficiency, 
fatigue is a prevalent symptom.89 We therefore decided to include the exercise testing in the 
analyses of possible relationship between cardiac sequelae and fatigue. We also wanted to 
explore a possible relationship between fatigue and physical performance that in case of 
impaired physical performance indirectly could indicate the effect of cardiopulmonary 
dysfunction and fatigue. However, this was not in accordance to the aim of the principal 
investigators. For our purpose the major objective for this examination would have been to 
test exercise capacity. Such as test would include measurement of aerob capacity, peak 
oxygen uptake, gas exchange, and lung function including spirometry. 
The MRI procedure 
In the study described in Paper V, brain MRI examinations of HDS with and without fatigue 
were compared, in order to find possible explanatory factors to fatigue. The MRI 
examinations were performed on a 1.5-T MRI (Marconi Edge; Marconi, Cleveland, Ohio). 
The imaging protocol consisted of sagital T1-weighted images (TE/TR 12/240) and axial 
proton-weighted (TE/TR=16/3000), T2-weigthed (TR/TE=96/3000) and FLAIR –images 
(TE/TR=80/6433). Patients with pathological MRI-findings were reexaminated with MRI 
after 20-26 months in order to evaluate the stability of the findings. All images were analyzed 
independently by two radiologists, who were blinded to the identity of the patients.  
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Statistical analysis 
Different statistical methods have been used in the different studies, and details are described 
properly in the respective papers. Standard descriptive statistics were employed to describe 
the distribution of fatigue, HRQoL and anxiety/depression scores at the different assessments. 
Differences in medical and demographic characteristics were tested by chi-square tests 
(nominal categorical variables) and two-sided t-test (independent sample) or Wilcoxon`s test 
(two-tailed) when appropriate (Paper II). Associations between fatigue and biological 
variables were tested by two-sided t-test (independent sample), Anova`s oneway analysis of 
variance, and chi-square statistics (nominal categorical variables). Bivariate associations were 
also analysed by Pearson`s correlation correspondingly Spearman`s rank test when 
appropriate. In Paper II and IV multiple comparisons forced a correction of p-value, and 
Bonferroni and Tukey were the correction methods applied.  
Multiple regression analysis was used to detect relationship between fatigue and selected 
possible predictors as independent variables (Paper IV). Physical fatigue was included as the 
dependent variable in a linear regression model whereas fatigue cases (dichotomous variable) 
was selected as the dependent variable in a multiple logistic regression model. The selection 
of the independent variables was based on knowledge about possible predictors of fatigue in 
previous studies, and on results of the univariate analysis in the current study. 
Different approaches were taken to evaluate the validity of the EORTC QLQ-C30 fatigue 
scale, FA (Paper I). Pearson’s correlations were used to explore the relations between the FA 
and the FQ scales and single items (concurrent validity). Evidence of items convergent 
validity was defined as a correlation between one item and its own scale. Construct validity 
was evaluated by the use of principal factor with varimax rotation including all the fatigue 
items in the two questionnaires. The criteria for determining the number of factors were an 
eigenvalue above 1.0 and a visual inspection of the scree plot. 
Clinical validity of the two measures, the extent to which the questionnaires scores are able to 
discriminate between subgroups of patients differing in terms of symptom burden or clinical 
status, was evaluated by use of two strategies: known groups comparisons and squared t –
statistics.61 The advanced cancer patients were dichotomised according to a selection of 
clinical variables. Student`s t-test for each instrument separately were used to examine 
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differences in fatigue between the dichotomised groups. The ratios of the squared t-statistics 
(t2/t2) were used to demonstrate the relative sensitivity of the two instruments. Since the FQ 
was regarded as the “gold standard”, the t-statistics of the FQ were used as the denominator. 
In order to explore the measurement agreement between the two fatigue scales, fatigue scores 
measured by FA in relation to different fatigue levels measured by FQ were plotted. 
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Main results and summary of papers 
Paper I 
The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer 
survivors
In this paper the validity and the sensitivity of the fatigue scale in EORTC QLQ C30 were 
evaluated.
The EORTC QLQ-C30 is one of the most commonly used HRQoL questionnaire developed 
for use in cancer patients. The EORTC QLQ-C30 includes a three-item fatigue subscale, FA. 
It is limited knowledge about the validity, performance and sensitivity of FA as compared to a 
fatigue-specific instrument. The aim of the study was to validate the FA against the FQ, a two 
dimensional fatigue specific instrument which measure physical (PF, 7 items) and mental 
(MF, 4 items) and total fatigue (11 items). 
The material included two different cohorts: A. Patients with advanced cancer included in a 
prospective randomized study of palliative radiotherapy (cohort 1, n=238). B. Patients with 
leukaemia and malignant lymphoma curatively treated with stem cell transplantation and 
HDC (cohort 2, n=128). 
The FA correlated higher with the PF scale (r = 0.67-0.75) as compared to the MF scale 
(r=0.49-0.61) within the FQ. The item-scale correlations between the FA items and the PF 
scale were consistently higher than between the FA items and the MF scale. A factor analysis 
including all the items within the FA and the FQ identified two factors. All the FA items 
loaded on a physical fatigue factor (0.70-0.85). A floor/ceiling effect, indicating a high 
number of respondents with lowest, respectively highest scores, was observed more 
frequently in the FA as compared to the FQ. In the palliative care population a ceiling effect 
with highest possible scores was observed in 10.9% of the patients with the FA versus 2.9% 
with the PF in FQ. In cancer survivors a floor effect with lowest possible scores was observed 
for the FA in 24% of the patients versus 0% for the PF in FQ. In the palliative care population 
the PF discriminated better between diagnostic groups with different levels of fatigue than the 
FA did. A plot of fatigue measured by the FA against the PF illustrated a poor measurement 
agreement between the two scales indicating a poor ability of the scales to capture the same 
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patient population. These findings in addition to the floor/ceiling effects may indicate a 
suboptimal sensitivity of the FA. 
In conclusion, the EORTC QLQ-C30 fatigue scale FA is measuring physical fatigue. A 
floor/ceiling effect seems to appear for the FA. The validity of the EORTC QLQ-C30 fatigue 
scale is to be questioned for use in palliative care patients. In studies with fatigue as an 
important endpoint, a domain specific instrument should therefore be added.  
Paper II 
A 3-5 years prospective study of health related quality of life, fatigue, anxiety and 
depression after stem cell transplantation 
This paper present the result of a prospective study of fluctuations in HRQoL, fatigue and 
psychological distress during the course of HDC followed by allogeneic or autologous stem 
cell transplantation (SCT/ASCT) and during the periods of rehabilitation. A follow up to at 
least three years post treatment were conducted with the objective to explore fatigue in 
patients with haematological or lymphoid malignancy as a risk group of developing chronic 
fatigue documented by others. 
The study populations were patients with leukaemia receiving allogeneic stem cell 
transplantation (SCT) and patients with malignant lymphoma receiving autologous stem cell 
transplantation (ASCT). Lymphoma patients receiving standard chemotherapy (CT), and data 
from general population were used as comparisons groups.  
At baseline there were clinically significant differences across the two transplant groups in 
direction of better HRQoL in the SCT group. The differences in global QoL and fatigue were 
most pronounced in favour of the SCT group. At 1 year post treatment the SCT group 
reported significantly higher functional scores and less symptomatology as compared to 
ASCT and CT patients. This pattern remained stable at the assessment 3-5 years after 
treatment. The functional and symptom scores were mainly unchanged in all groups at 3-5 
years follow up as compared to 1 year. All groups reported higher levels of fatigue as 
compared to the general population 3-5 years after treatment, however only in the ASCT 
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group a significantly higher level (28%) of chronic fatigue was found as compared to SCT 
group (11%) and norms (9%). The ASCT group reported additionally poorer role, cognitive 
and social function as compared to the norms. No differences were found in anxiety and 
depression between the treatment groups at baseline, 1 and 3-5 years after treatment or as 
compared to the norms.  
In conclusion, the majority of the patients perform well after 3-5 years post treatment as found 
at 1 year assessment. The ASCT patients demonstrated poorer function and more symptoms 
as compared to SCT and CT group and as compare to general population. This study also 
confirmed previous studies reporting more fatigue in lymphoma patients and that it last for 
many years after treatment. 
Paper III 
High level of fatigue in lymphoma patients after high dose therapy 
As highlighted in Paper II, medical late effects and secondary effects on subjective health like 
fatigue are of concern after HDC supported by stem cell transplantation. Changes in the 
endocrine system such as gonadal dysfunction and in the immune system are well known 
medical complication to autologous bone marrow transplantation (ABMT), but an association 
to high levels of fatigue has never been explored in these patients. This paper presents a cross 
sectional study of subjective health and possible underlying factors that might explain fatigue 
in patients with malignant lymphoma treated with HDC and ABMT. The patients population 
constituted 33 lymphoma survivors (median age 39 years), and observation time since ABMT 
were 4-10 years. The patients’ scores were compared to general population norms. 
Fatigue was highly prevalent compared to general population (p<0.001). Females reported 
significantly more physical (p<0.01) and total fatigue (p<0.05) as compared to males. Patients 
reported reduced function status and in particular reduced role, cognitive and social function 
and financial difficulties as compared to general population (p<0.01). Females demonstrate 
poorer HRQoL than males when compared to gender-specific references. Patients who were 
partly employed (=6) or not employed at all (n=8) were more fatigued than full-time 
employed (n=18) (p<0.05). No disease or treatment variables were significantly associated 
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with high levels of fatigue. The relationship between fatigue and endocrinological and 
immunological abnormalities were explored. Gonadal dysfunction was found in the majority 
of the patients, but no statistically significant endocrinological explanation of fatigue could be 
demonstrated. The levels of cytokines IL-6 and soluble receptors of TNF-p55 and TNF-p75 
were slightly elevated and only a weak association was found to fatigue. 
In conclusion, the high level of fatigue among female long-term survivors after ABMT may 
be related to the gonadal dysfunction, but further larger studies are needed to confirm such an 
association. Even though no clear association between cytokine level and fatigue was found, 
the effects of long term exposure of cytokines on central nervous system, on muscles, on 
endocrine system and finally fatigue, is of special interest to investigate further in cancer 
patients. The high level of fatigue among part-time and not employed patients is of major 
concern. Impaired role function is found to be associated with ability to work, and high levels 
of fatigue imply that returning to work might be problematic. 
Paper IV 
Late medical complications and fatigue in Hodgkin´s Disease Survivors 
Late cardiopulmonal and thyroid complications are frequently reported and well documented 
in HDS. In this study we explored whether fatigue in patients treated for HD can be explained 
by cardiac, pulmonary and thyroid function after ended treatment. 
Two dataset from the same cohort of patients were combined. Four-hundred and fifty-nine 
patients treated for HD at the NRH from 1971 to 1991 were included in a cross-sectional 
follow-up study of subjective health status including fatigue. A subcohort of HDS treated 
from 1980 to 1988 were included in a separate study in which long term cardiac, pulmonary 
and thyroid complications were assessed. Mean observation time since treatment was 9 (± 3) 
years. All patients had received radiotherapy, and 63 patients had received additional 
chemotherapy. The present study is comprised of the 92 patients (mean age 37 years, range 
23-56) who participated in both studies. 
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Above one third of the patients (n=34) had pulmonary dysfunction. HDS with pulmonary 
dysfunction were more fatigued than HDS with normal pulmonary function (p<0.05). Gas 
transfer impairment was the most prevalent type of pulmonary dysfunction, and three times as 
many patients with gas transfer impairment reported chronic fatigue (duration 6 months or 
longer) compared to patients without pulmonary dysfunction (48% vs 17%, p<0.01). In a 
multivariate analysis gas transfer impairment was the only significant predictor of physical 
fatigue (p=.01) and of fatigue cases (p=.002). Approximately 50% of the patients had 
significant cardiac pathology, but they did not report more fatigue than HDS without cardiac 
sequelae. A trend in direction of more physical fatigue was observed among HDS with 
coronary artery disease (CAD, n=6) versus HDS without CAD (PF 12.7 VS 9.4, p=.05). 
Above 50% had thyroid dysfunction and one third were euthyreot, while 15 patients had 
hypothyroidism with replacement therapy. The latter groups reported more fatigue as 
compared to HDS with thyroid dysfunction (p=.02).  
In conclusion, pulmonary dysfunction is associated with chronic fatigue in HDS. The lacking 
differences in fatigue level between HDS with and without cardiac pathology may be related 
to a possibly limited severity of the cardiac pathology. Both pulmonary and cardiac 
dysfunction due to late effects after cancer therapy are expected to progress in the course of 
time after therapy. HDS with hypothyroidism and replacement therapy reported more fatigued 
as compared to HDS with thyroid dysfunction. The response evaluation of replacement 
therapy of thyroid dysfunction after treatment for HD needs further investigation. 
Paper V 
Brain lesions in chronic fatigued survivors of Hodgkin´s Lymphoma - an explorative 
study
Fatigue is a predominant symptom in chronic inflammation and non-malignant diseases such 
as MS, systemic lupus erythematosus and chronic fatigue syndrome. Pathophysiological 
factors including brain abnormalities have been suggested as possible causes to fatigue in 
these cohorts of patients. The aim of this study was to investigate possible relationships 
between MRI brain lesions and fatigue in HDS. Fatigue was assessed in 53 adult patients 
treated for HD in the periode 1987 to 1997, without evidence of active disease in 1997. 
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Eighteen patients were classified as fatigued, and 13 of these patients were examined for the 
presence of MRI brain lesions. An age- and gender matched population of HDS without 
fatigue was included as a comparison group.  
Two of the 13 HDS with fatigue had pronounced coalescent T2-hyperintense white matter 
lesions in both cerebral hemispheres, one had subtle T2-hyperintense white matter lesions and 
one had a cerebellar infarction. Two of the non-fatigued HDS had subtle punctuate white 
matter lesions in both cerebral hemispheres. Analysis of cerebrospinal fluid and blood serum 
in patients with brain MRI lesions did not confirm any relationship between examinations 
related to immunologic mechanisms and fatigue and/or MRI lesions. 
Fatigue in HDS is a complex phenomenon. An association between cerebral white matter 
lesions and fatigue were found in the present study. Systemic effects of radiotherapy and 
chemotherapy, or brain tissues damage caused by the disease itself are possible explanations 
for these findings. This study calls for further studies of the causality for fatigue in HDS.
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Discussion
Subjective outcomes or HRQoL is more often used in clinical studies today as compared to 
10-20 years ago. New important findings are published with HRQoL as the main outcome, 
such as in palliative studies.196-198 It is also used in studies aiming at life prolongation and 
curation as secondary outcome as well as in long term survivors after intensive curative 
treatment.171
In this thesis the overall aim is to improve the scientifically understanding of fatigue in 
lymphoma patients. The attempts to address possible etiological factors related to fatigue or to 
causes to fatigue in HDS may give empirical evidence for addressing some specific 
hypothesis in future studies.
As in research in general the validity of the subjective outcomes are of crucial importance. 
Two aspects of the validity of the EORTC QLQ C30 have been addressed, namely the 
dimensionality and the sensitivity of the fatigue scale within this QoL instrument. 
One obvious reason to focus the work on the EORTC QLQ-C30 is the common use of this 
instrument in cancer research as well as in clinical practice. It was originally developed as a 
cancer specific instrument and validated in a general cancer population internationally,62 and 
nationally.199 These validation procedures have only to a limited extend compared the 
behaviour of the instrument in different populations directly and/or by using a domain specific 
instrument as a “criterion”. Recently the EORTC QLQ-C30 was compared with the SF-36 in 
chronic non-malignant pain patients by our group.200
Fatigue assessment 
A lack of consensus surrounds on how to assess fatigue. Since fatigue is a subjective 
phenomenon it is agreed that it should be measured by patients’ self assessment. A number of 
fatigue instruments exist, both uni-dimensional and multidimensional.64 All measurement, 
from blood pressure to HRQoL assessment including fatigue, should satisfy basic properties. 
These are validity, reliability, sensitivity and responsiveness. For subjective symptoms such 
as fatigue, which is not directly observable, or easily quantified, a need exist for reliable 
instruments that measure what it is intended to measure in different patient population, and 
instruments that is useful for its intended purpose.
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Floor-ceiling estimates were used in this thesis to assess the sensitivity of FA, which is the 
instrument’s ability to discriminate between patients with a very high and very low level of 
fatigue. It was shown that the instrument behaved differently between the palliative patients 
and the leukaemia/lymphoma survivors (Paper 1).201 This finding indicates one of several 
challenges in the generalizability of validation studies. First of all, this indicicates that these 
aspects of validity ie ”floor/ceiling effects” probably are cohort dependent phenomenon, 
which means that an often cited assumption in several validation studies ,“the instrument is 
found valid for use in cancer patients”, should not necessarily be accepted as a general 
statement unless the validity have been evaluated in a series of cohorts. The findings in our 
study underline the importance of validating instruments in various cohorts with variations in 
frequency and intensity of symptoms, such as fatigue. The cohort dependent validity issues 
are rarely taken into consideration in instrument development as well as in the further critical 
evaluation of its use. The ideal HRQoL instrument should yield similar high level of validity 
independent upon cohorts. However, it is probably too much to expect, since most of the 
instruments have been specifically developed for specific types of distress and/or are disease 
specific symptoms. As a consequence of these assumptions, a general statement high degree 
of validity must be judged critically. For example, the different disease specific instruments, 
their development and validation procedure and the results should be carefully assessed 
before one decides to include a given instrument in a study.  
As expected, the FA seems to measure primarily the physical dimension of fatigue in both 
cohorts. In other words, this finding is robust when comparing cohorts. It is important to be 
aware of, when interpretating the FA in the EORTC QLQ-C30, that only one dimension of 
fatigue is measured, which is rarely discussed in any detail, 62, 202 136, 176, 203 however the 
question about multidimensionality have also been addressed previously in relation to 
validation of the FA.82
This phenomenon points towards another challenge in outcomes interpretation namely the 
content of the scale or a measure. In general terms before deciding on a measure in a study, 
the researcher should carefully look into each question in a scale in order to understand the 
content of the measure. In other words one needs to carefully assess and judge the content on 
a detailed level and see how it fits with the research questions or hypothesis. Fatigue is in 
most patients considered to consist of two dimensions, physical and mental. Thus content as a 
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criterion, a summary scale of fatigue should measure both of the dimensions. The FA of the 
EORTC QLQ C30 measures only physical fatigue accordingly to our empirical data. By 
inspecting the content of the measure, the following items are included: “Did you need to 
rest?”, “Have you felt weak?” and “Were you tired?” This inspection would probably from 
most peoples perspective be in accordance with the empirical findings in our study. These 
findings also shed lights on one major challenge in symptom assessment in general and 
fatigue assessment specifically, the lack of any international consensus on how to measure 
fatigue in cancer care. 
Another important finding in this study is related to the translation of single items from 
English to Norwegian. Both questionnaires have been translated according to international 
standards,204 but still discrepancy was found. The English word “weak” which is found in one 
of the fatigue items in both FA and FQ is translated differently in the two instruments, namely 
as “slapp” (FA) and as “svak” (FQ). This finding underlines first the importance of 
standardised procedures and documentation of translation of questionnaire followed by a 
detailed validation of the language specific instruments, and ideally followed by retesting in 
ongoing empirical studies in the following years. Secondly, it is an argument to limit the 
number of instruments to be used in clinical studies. This will challenge the international 
research community to agree upon common standards, and ideally to develop new instruments 
in an international setting. By developing questionnaires in multi-language collaboration 
wording and phrases can be adapted up front to fit to the main type of languages involved in 
the development process.  
A need for long term follow up  
HRQoL is often measured in oncological studies today, either as a primary, secondary or even 
tertiary outcome. In palliative studies where symptom control and/or function improvement 
often are the primary aims, HRQoL and/or symptom checklists will be used to measure the 
primary outcomes, and survival and tumour response may be of less importance. On the other 
hand, in curative treatment cure rate and survival is considered in most studies to be the 
primary outcome, and quite often subjective symptoms, i.e. HRQoL to be of less importance. 
During the last decade several follow-up studies have shown that the long term side effects of 
curative treatment is more pronounced than first expected.205-209 Serious side effects have not 
76
been detected earlier due to lack of prospective systematic follow-up of patients 
(http://odin.dep.no/repub/98-99/stprp/3). This might have happened because the focus during 
the 1980`s and 1990`s was to improve cure rate and survival while much less attention were 
given to a systematic follow up of possible treatment related side effects. Patients were 
primarily followed in order to detect relapse of the cancer disease. During the last decades 
more attention have been given to the need for systematic follow up and assessment of long 
term effects after curative treatment.2, 206, 210-213
In one of the studies in this thesis, a prospective follow-up design was chosen including a long 
term assessment 3-5 years after curative treatment were given (Paper II).214 This study 
documented the value of following patients over time in order to better understand the pattern 
of subjective symptoms. The long term follow-up design detected a significant level of 
fatigue, particularly in the lymphoma patients as compared to leukaemia patients. 
Another important argument for the need for long term follow up is the findings of reduced 
working ability in a small fraction of the ABMT cohort 4 to 10 years post treatment (Paper 
III).215 Approximately half of the patients in the study were working part time or were 
unemployed. There were clinically and statistically significant differences in fatigue level in 
direction of more fatigue among lymphoma survivors being disabled as compared to those 
who were full-or part-time employed (Paper III).215 This is in accordance with the few earlier 
studies of fatigued lymphoma survivors. In these studies it is reported reduced working 
ability,107 more working difficulties among HDS as compared to survivors of testicular 
cancer,69 and higher percentage of unemployment among HDS than the general population,216
All these studies have in common a long follow-up time with range from 8-14 years since 
diagnosis.
Level of function 
Despite a high level of fatigue and reduced working ability in subcohorts, the general 
impression is that patients who undergo high dose chemotherapy and stem cell support 
recover well after transplant. Overall QoL, level of function, ability to return to work are 
reported to be reasonably good in previous studies.172, 217-221 Impaired physical functioning 
and increased fatigue are the main HRQoL domains that is reported to be of any clinical 
significans.171, 219-225 Most studies included small cohorts without comparison groups, and had 
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a relatively short follow-up time, seldom beyond three months post transplant which may be 
considered as a limitation. Long term follow up of the function level several years after 
treatment should be assessed with a prospective design and repetitive measurements. To our 
knowledge, no prospective study has assessed fatigue with a longitudinal design beyond the 
first year after transplant.
In this thesis it is shown that the lymphoma survivors after ABMT or ASCT report impaired 
functioning and more symptoms as compared to general population (Paper II and III),214, 215
and compared to leukaemia survivors (Paper II).214 When data were broken down to age and 
gender and matched with general population, role and cognitive function as well as global 
QoL were more impaired in the ASCT patients 3-5 years post treatment as compared to the 
SCT patients (Paper II). 214 The longitudinal follow up confirm this pattern of persisting 
dysfunction among the ASCT patients in that these impairments were reported at baseline 
before transplant as well as 3-5 years post transplant in spite of improvements in other 
function scales during follow-up. 
The findings in the lymphoma patients confirm a pattern of dysfunction as also indicated in 
the existing literature69, 107, 216 Why lymphoma patients seem to be more affected than other 
cancer patients after treatment is probably multifactorial as discussed in this thesis.  
Both the role and cognitive function impairments are of special concern for the patients. 
Impaired functions reported so many years after ending treatment could indicate a significant 
health problem. Role function has been particularly associated with ability to work. Studies 
have operationalized returning back to normal life as resumption of professional and private 
roles.219, 221, 226, 227 Work-related problems, inability to resume social role, financial problems, 
worries about the future and fear of relapse are frequently reported problems among cancer 
survivors.217, 225, 228-232 This pattern is retrieved in Paper III, even after 4-10 years post 
transplant approximately half of the patients were working part time or were unemployed. 
Financial difficulties was significantly more frequently reported among the lymphoma 
survivors after ABMT, as compared to general population (Paper III).214, 215 Financial
problems might be a natural consequence of the employment status, but may also reflect 
general difficulties with loan and insurance coverage for people with a history of cancer. Such 
issues were not of concern earlier when the curation rate of cancer were low, and is a 
reminder of the challenges that the long term effects may have on cancer survivors.233
78
Cognitive function is an important domain in HRQoL. Some of the most frequently assessed 
domains are concentration, memory and attention. Studies have reported that patients after 
chemotherapy complain of difficulties in thinking and memory.53-57, 160, 223, 234, 235 Our studies 
demonstrate significantly impaired cognitive function longitudinal assessed in patients during 
and until 3-5 years post transplant (Paper II) 214. Our cross sectional study of lymphoma 
survivors after ABMT demonstrated that cognitive function is impaired even up to 4-10 years 
after ABMT when compared to general population (p<0.001) (Paper III).215 These findings 
are in accordance with the existing literature of cancer survivors after chemotherapy or 
transplant.
The assessment of cognitive function by mean of a self report HRQoL questionnaire have 
been critizised.58, 236 By inspection, the two items of the cognitive function scale CF in the 
EORTC QLQ-C30 are identical with two of the four items of the mental fatigue scale (MF) in 
the FQ. A high item-by item correlation between the items in CF and MF indicated a strong 
correlation between these two scales (data not presented). This probably illustrate that similar 
phenomenon have different names in different instruments. Other types of methodology such 
as neuropsychological test should therefore be performed in further studies. 
Why are some patients more fatigued than other? 
There are probably several explanations to the inter-individual variability of fatigue. In order 
to investigate causality in general, a prospective design is preferable and the study samples 
need to be large enough. Before one possibly can embark on large scale studies, one should at 
least have “candidate” factors that may cause fatigue. 
At the time our study was planned little knowledge existed on causes of fatigue. Therefore 
several variables were investigated. Associations, as shown in our studies are not any “prove” 
of a causal relation. For an association to be accepted as causal, certain criteria have to be 
fulfilled. First of all, the association should not be a result of coincidence. Furthermore it 
should not be a result of systematic error due to selection bias, assessment error or caused by 
any confounding variables.237 According to B.Hill, the power of the association, (i.e. 
expressed by relative risk), consistent findings in several studies, cause and effect in the right 
order and the possibilities of biological comprehensibility are some main criteria of causality 
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while the only absolute criteria is the time relation between cause and effect.238 Taken all 
these issues into consideration our studies should be regarded as hypothesis generating with 
regard to possible causality of fatigue in cancer disease survivors in general and in HDS 
specifically. 
“Causes” to fatigue
Fatigue is a final common endpoint for several diseases and conditions, and will therefore be 
found in several populations with more or less impact on the patients` subjective experience 
of health. Pulmonary, cardiac and endocrine function was targeted in this thesis as 
“candidate” factors that may possible cause fatigue in patients treated for lymphoma . Late 
effects within these organs systems after treatment for both HD and NHL are common , and to 
our knowledge no study have investigated whether organ dysfunction can provide possible 
explanation to fatigue among survivors of HD and NHL.  
Pulmonary dysfunction 
In this thesis we found that pulmonary dysfunction in HDS treated with radiotherapy alone or 
in combination with chemotherapy was significantly related to increased fatigue (Paper 
IV).239 No major associations were found between cardiac sequelae or endocrine dysfunction 
and fatigue in the cohort investigated. How valid are these finding? Some important aspects 
are to be commented upon to shed light on these findings. 
The examinations of cardiopulmonary and endocrine function and of fatigue were performed 
at two different time periods. The cardiopulmonary and endocrine function was explored in 
1993.170 The assessment of fatigue was performed in 1994.240 The observations were cross-
sectional with a certain time difference between the assessments. The follow-up period is 
however long, and the time interval between the two assessments do probably not affect the 
results of the analyses. Despite the time interval, the study was not designed to assess 
pulmonary pathology that may cause fatigue. A cross sectional evaluation of the 
cardiopulmonary status offer only a picture of the situation now, and perform no additionally 
information of the situation before or the development of cardiopulmonary dysfunction and 
related symptoms over time. As we lack baseline information about fatigue, no objective 
evaluation of the cardiopulmonary function before start of the treatment for HD exits. It is 
however assumed that the cohort of HDS had a baseline normal lung function.170 The cross 
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sectional design do not prove any causality, but generate a hypothesis that HDS develop 
pulmonary pathology also develop more fatigue. This hypothesis needs to be investigated in a 
prospective study with larger cohorts. 
Fatigue is an unspecific symptom prevalent in several chronic conditions such as chronic 
pulmonary diseases, COPD, and chronic heart diseases, diseases inwhich also dyspnoe is a 
prominent symptom. In studies of COPD patients report they have difficulties to distinguish 
between fatigue and dyspnoe.241 Fatigue and dyspnoe may occure at the same or at different 
times in different patients but may be symptoms of the same disease. Therefore, there is a 
possibility that our assessment of fatigue have included patients with a subjective experience 
of dyspnoe more than fatigue, mainly due to the general uspesific characteristics of fatigue 
more than to insufficient methods of assessments. 
We can however not exclude that the findings in our study indicate that there is a causal 
relationship between pulmonary dysfunction and fatigue. Lung fibrosis is one of the most 
frequent chronic pulmonary complications after radiation therapy and is a major factor in the 
development of gas transfer impairments. Lung fibrosis was found in 76% of the HDS with 
gas transfer impairments in our study. The cardinal symptoms of lung fibrosis is dyspnoe. The 
arterial oxygen desaturation following pulmonary abnormalities may lead to more dyspnoe 
during activity, which again result in avoidance of activity and finally lead the patients into a 
negative circle with further decondition as a result. Studies from HDS as well as from patients 
with COPD have shown that dyspnoe is the exercise limiting symptom.242, 243 Dyspnoe in 
excertion was also reported by almost one third of the patients investigated in our study and 
most pronounced among HDS treated with both radio- and chemotherapy (Paper IV).239
Reports of positive relationship between exercise related improved oxygen use and improved 
fatigue/dyspnoea support this assumption.152, 153
Cardiac dysfunction 
Cardiac pathology did not explain fatigue in the HDS investigated in our study. However, 
higher level of fatigue was found among patients with coronary artery disease (CAD) as 
compared to those without CAD. Minor severity of the cardiac pathology and short 
observation time may be some reasons for the lack of a possible association between cardiac 
pathology and fatigue. A longer observation time would probably uncover increased number 
of patients with cardiac pathology, on the other hand will longer follow up periode also 
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weaken the relationship between disease, treatment and symptoms of fatigue. One need to 
take into consideration also a “natural” non cancer related development of cardiovascular 
disease as the population are getting older in long term follow up studies.  
Several studies have evaluated cardiovascular status on long-term survivors treated with chest 
radiotherapy in various populations in terms of age, diagnosis and/or treatment.195, 244-246. In a 
recent study with multiple screening of HDS 6-27 years since diagnosis, a serial of 
unexpected, clinically significant cardiovascular abnormalities were discovered although the 
patients were asymptomatic and reported their overall health as good.247 The endothel injury 
from radiation therapy is first of all a progressive injury which will develop atherosclerosis 
and coronary arterty disease over time. First then the injury will be symptomatic for the 
patients. The subcohort with symptomatic CAD in our cohort is small, and may possibly be 
due to short observation time. The results of several studies undertaken in the 1980 aiming to 
assess risk of CAD after mediastinal radiation therapy have been inconclusive.195, 248-250
However, analyses have subsequently shown a clearly increased risk for CAD and myocardial 
infarction after mediastinal radiation therapy for HD.248, 251, 252 Fatigue is a cardinal symptom 
in patients with chronic heart diseases, and with negative effects on physical activity and 
quality of life.253 Therefore, cardiovascular status should be followed in patiens treated for 
HD and NHL to capture when these subclinical findings developen clinical manifestation. In 
further studies cardiovascular pathology and specifically CAD should be considered as 
candidates to explain fatigue or as one of several possible causal factors. 
Endocrine dysfunction 
The weak association between fatigue and thyroid function in HDS needs further 
investigation. The sample sizes in our study were small, the majority of the HDS had thyroid 
dysfunction or were substituted for hypothyroidism. Hypothyroidism develops gradually, and 
the cross sectional design is not an appropriate design to test the association between 
symptom and disease. The documentation of clinical and biochemical effects of substitution 
therapy for hypothyroisis and other endocrine dysfunctions in HDS is sparse, and the 
evaluation of treatment effects upon symptoms is unclear. The endocrine system is complex 
and difficult to evaluate. Diurnal variation, physical and psychological factors influence the 
hormone levels. A prospective evaluation of fatigue and thyroid function in order to 
investigate the relationship between biochemical hypothyrosis and fatigue would be a 
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preferable design to evaluate this relationship. The next would be to perform a clinical 
controlled intervention study in well defined cohorts with fatigue as primary endpoint in order 
to evaluate the effects of substitution therapy. 
The gender differences in fatigue among lymphoma survivors after ABMT as was 
demonstrated in paper III may be explained by the female gonadal toxicity or other unknown 
gender related factors.215 The female lymphoma survivors after ABMT reported significantly 
more fatigue as compared to males. The literature of gonadal dysfunction and related 
symptoms after curative cancer treatment is scarce, and consequently it is difficult to conclude 
about the relationship between fatigue, gender and hormonal dysfunction. The endocrine 
hypothesis in relation to fatigue is therefore insufficient explored, and a thorough 
investigation of the HPA axis in lymphoma survivor should be performed.  
Immunological abberations and brain lesions 
In the literature several reports have discussed that fatigue in general122, 155 as well as in HDS 
113 is associated with high levels of cytokines. The specific cellular morphology of HD and 
NHL may result in high level of cytokines, and therefore it seems relevant to investigate this 
relationship. Whether the cytokine levels are elevated also in HDS several years after 
treatment is unclear. We selected the cytokines on the basis of previous research in this field, 
and the assessment was conducted in order to explore whether fatigue is associated with high 
levels of cytokines in HDS and NHL survivors. We did not capture any abnormalities in 
cytokines levels. Due to the cross sectional design of this study no baseline estimates of 
cytokines were available. This is a weakness of this kind of design and it is obvious that 
prospective design should be chosen also in this setting. 
It has been speculated whether fatigue can be associated with minor brain lesions.254, 255 MRI 
has been used in other patient population exploring fatigue in patients with cerebral 
pathology.88, 113, 164, 254, 256, 257 In our study two of the 13 HDS with fatigue had pronounced 
coalescent T2-hyperintense white matter lesions (WML) in both cerebral hemispheres, one 
had subtle T2-hyperintense WML and one had a cerebellar infarction (Paper V). Two of the 
non-fatigued HDS had subtle punctuate WML in both cerebral hemispheres. These results are 
difficult to interpret as a possible etiologic explanation for fatigue in these patients. Cerebral 
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WML were found in both group of the HDS with or without fatigue, and express possible 
more a pathologic finding in the brain possible due to systemic effect of disease of HD or the 
treatment as it explain the fatigue experienced by these patients. A recent study could 
demonstrate specific alteration in activity of frontal cortex, cerebellum and basal ganglia in 
breast cancer survivors documented by functional neuroimaging 5-10 years after 
chemotherapy indicating a negatively impact on cognitive function due to cerebral effect of 
chemotherapy. To relate cerebral pathological findings to fatigue is challenging. It may 
depend on the localisation of the findings, and the direct and indirect effect of the lesions on 
mental or physical function. Which clinical manifestations are to be expected, and which 
cerebral lesions may explain or contribute to fatigue? As in other cross-sectional studies, we 
did not have any information about the patients` brain MRI before this examination performed 
as a part in our study. It may therefore be a weakness of this part of the study only to use the 
brain MRI to discover cerebral lesions that might explain fatigue. Complementary 
examinations such as neuropsychological tests could have been considered.55, 258 Secondly, a 
prospective study of patients with HD that included baseline cerebral MRI and assessment of 
fatigue before and after treatment would have been a more superior design.  
Conclusion
The results from this thesis can be summarised as follows: 
x This thesis have demonstrated that the EORTC QLQ C 30 fatigue scale, FA, is one- 
dimensional measuring physical fatigue.  
x Poor sensitivity of the FA in the EORTC QLQ C30 was found with major floor/ceiling 
effects and a poor ability to differentiate between diagnostic groups with different 
levels of fatigue.
x Fatigue and dypnoe is more frequent among lymphoma patients as compared to 
leukaemia patients 3-5 years after high dose chemotherapy and stem cell 
transplantation, and as compared to lymphoma patients treated with standard 
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treatment. Lymphoma patients report significantly more fatigue up to 10 years after 
transplant as compared to the general population.
x The lymphoma patients report clinical and statistical significantly impaired social, role 
and cognitive functions as well as poor QoL 3-5 years after transplant when compared 
with leukaemia patients after transplant and with lymphoma patients after standard 
treatment. These function scores were significantly lower as compared to the scores 
from the general population as well.  
x Fatigue in HDS treated with mantle field radiotherapy (85/92 patients) alone or in 
combination with chemotherapy was associated with pulmonary dysfunction. Gas 
transfer impairment was a significant predictor of physical fatigue and of chronic 
fatigue among the HDS. 
x A higher level of fatigue was found among HDS with coronary artery disease (CAD) 
as compared to patients without CAD. No other cardiac sequelae in the HDS 
investigated in our study were associated with fatigue in this cohort. In further studies 
cardiovascular pathology and specifically CAD should be considered as candidates to 
explain fatigue or as one of several possible causal factors. 
x Endocrine complications such as gonadal dysfunction and hypothyrosis were weakly 
associated with fatigue in lymphoma survivors. We still consider that late effects in 
the endocrine system may possibly be of clinical importance in cancer survivors in 
general and above all in lymphoma survivors after both transplant and standard 
treatment.  
x Fatigue in HDS is difficult to be explained by the MRI abnormalities presented as 
cerebral whiter matter lesion (WML) found in these patients, mostly due to few 
findings and the small sample size. 
x In HDS with fatigue and cerebral WML no clinical or biochemical indicators of 
immune dysfunction were found. No differences in levels of proinflammatory 
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cytokines IL6 and soluble TNF-Į receptors between lymphoma patients post 
transplant and age-and gender adjusted population values were found.  
x The clinical consequence of WML lesions will possibly be related to the localisation 
and the severity of the lesions. Cognitive impairment or mental fatigue in cancer 
survivors is associated with WML as systemic effects of radiotherapy or 
chemotherapy or the disease itself. With such small sample size and the lack of 
baseline information of WML pre-treatment, a causal relationship to fatigue is 
therefore difficult to evaluate. 
Future research 
With more than 50% of cancer patients surviving more than five years beyond diagnosis, 
oncologists are challenged to expand their focus from acute care to managing the long-term 
health consequences of cancer. Cancer survivors are at increased risk for several late and 
long-term effects of cancer and other comorbid conditions, and many also seek lifestyle 
change to reduce dysfunction and improve long-term health. The survivors fear of recurrence 
and the fact that many survivors may not be aware of potensial late effects is also critical for 
an improved survivorship care. Survivorship research should include clinical epidemiological 
research aimed at physiological and psychological aspects of cancer survivorship and gain 
knowledge about follow up, intervention and surveillance strategies. 
Based upon the studies in this thesis and new literature there are some issues to be raised with 
regard to future research. The main areas are: Assessment of fatigue and other relevant 
symptoms in prospectively designed studies, long-term follow up studies of fatigue, 
assessment of potential mechanisms for fatigue, and the clinical use of research findings. 
86
Assessment of fatigue 
It is an ongoing debate on how to improve the methods for assessment of functioning and 
subjective symptoms in cancer patients. With increasing interest to test interventions for 
fatigue and other bothersome symptoms it should be assessed in a clinical setting and this will 
require accuracy and efficiency.259 Computerized adaptive testing (CAT) enables precise 
assessment of fatigue without administration of a large amount of questions that the patients 
have to answer, and should be developed as a comprehensive tool both for use in daily clinic 
and in research.
Longitudinal studies of fatigue 
Trajectory of fatigue during cancer treatment and knowledge about persistent fatigue after 
cancer treatment is critical for an accurate understanding of post treatment fatigue. 
Prospective study design should be chosen, preferably including pre-treatment data. This 
design has three major advantages: The baseline values of fatigue will give more accurately 
the estimates of chronic fatigue corrected for baseline values during and after treatment. This 
design may uncover different trajectories of fatigue and possible risk factors for developing 
fatigue. Still there are few studies with a follow up beyond 5 years. Due to the adverse effects 
of fatigue future research should include evaluation of symptom burden, functional and 
employment status, and physical and emotional well being in the growing population of 
cancer survivors.
Long term follow up studies 
Long term follow up is of particular important to detect late effects of cardiac and pulmonary 
dysfunction. Organ failure may develop wih time and worsen the functions as the patients get 
older. The Cancer Registry of Norway holds a complete database of all cancer cases 
systematically collected by requiring information from the clinicians and the pathologists.1 By 
matching the data with the Register of Deaths at Statistics of Norway the mortality can be 
investigated. It is proposed that the mortality have changed in direction of increased non-
cancer related mortality as compared to the cancer-related mortality. If so, the treatment has to 
improve with the aim to reduce the non-cancer related mortality. Research on late effects 
based on such matching is sparse in the existing literature, and presumably because few 
countries have national cancer and death registers. 
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Causes of fatigue after cancer treatment 
Future studie should include more comprehensive assessment of potential mechanisms of 
fatigue after cancer treatment. Fatigue is probably caused by multiple factors which may 
differ for different patients. Possible mechanisms within the cardiopulmonary and endocrine 
system have rarely been investigated earlier like in this thesis, and need further investigation 
above all in frame of longitudinal and long term follow up studies. Promising mechanisms 
have also been identified within the immune and neuroendocrine system, supporting the 
hypothesis that inflammatory alterations underly mechanism for persisting fatigue. More 
extensive measurements of the inflammatory signaling activity in ordre to identify 
immunological biomarkers for post treatment fatigue is in focus, and need to be performed in 
different diagnostic groups of cancer survivors with persistent unexplained fatigue. 
As a final comment, the physicians generally underestimate the level of fatigue and its impact 
on patients HRQoL and functioning. This statement is based on both scientific documentation 
and from clinical experience.260, 261 The fact that the physicians believed pain to be more 
debilitating than fatigue, may concern the physician trend to give attention to symptoms that 
more easily can be treated. Few treatment options do exist that quickly relieves fatigue, and 
thus the willingness to discuss fatigue with the patients may be low. It is important to be 
aware of that patients often associate fatigue with active disease and may misinterpret fatigue 
as a symptom of relapse. Therefore, it is important to improve the understanding of fatigue as 
a subjective phenomenon.  
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Abstract
With the success of high dose therapy supported by autologous bone marrow transplantation 
(ABMT) for malignant lymphomas, medical late-effects and secondary effects on subjective 
health, like fatigue, are of concern. Fatigue is poorly understood and correlates have been barely 
addressed. Health-related quality of life (HRQL), fatigue, and correlates to fatigue, including 
endocrinological status and serum levels of interleukin-6, tumor necrosis factor, and soluble 
tumor necrosis factor receptors, were investigated in a cross-sectional study of 33 lymphoma 
patients (median age 39 years) 4–10 years after ABMT. The survivors were compared to 
general population norms. Fatigue was highly prevalent, and females reported signiﬁcantly 
more fatigue and impaired HRQL compared to males and the normal population. Gonadal 
dysfunction was found in the majority of the patients, but no statistically signiﬁcant 
endocrinological or immunological associations with fatigue could be demonstrated. The high 
level of fatigue among female long-term survivors after ABMT may be related to the gonadal 
dysfunction, but further studies of possible mechanisms behind fatigue are necessary. J Pain 
Symptom Manage 2000;19:446–456. © U.S. Cancer Pain Relief Committee, 2000.
Key Words
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Introduction
High-dose therapy supported by allogenic or
autologous bone marrow transplantation (ABMT)
or peripheral progenitor cells support has rap-
idly gained acceptance as a curative treatment
option for a number of cancers like leukemia
and lymphoma. From being a highly experi-
mental procedure, only given in advanced
stages of malignant diseases, the utility of high
dose therapy with allogenic and autologous
stem cell support has expanded during the last
several years,1–3 leading to an increasing num-
ber of long-term survivors. These therapies are
generally performed in young patients with
long life expectancy. Despite the clinical suc-
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cess achieved with this treatment, the long-
term toxic effects are of concern .1–8
Mortality and somatic-related morbidity
have been the main outcomes in the clinical
investigations after high dose therapy with
stem cell support. During recent years, how-
ever, attention has been directed towards
health-related quality of life (HRQL) as an
endpoint after such treatment.5–8
HRQL is defined as a multidimensional con-
cept consisting of physical, psychological and
social dimensions.9 Fatigue or vitality is a sub-
domain of HRQL, and is included in most
HRQL-instruments. Fatigue is usually defined
as a subjective phenomenon, and in the ab-
sence of objective measures, measurements of
fatigue rely on subjective reports from patients
themselves.10 Patients in several follow-up stud-
ies after BMT report their HRQL as rather
good.8 However, deficits in specific domains in
HRQL are frequently reported.8,11 Fatigue was
one of the three most frequently reported cur-
rent problems in a study of 125 adult long-term
survivors (6–18 years) of BMT/ABMT.12 In a
study of 29 adults 1–8 years after BMT, 76% re-
ported “feeling tired”.13 Further, 50% reported
fatigue and reduced energy level in a study of
24 adults 12–38 months post-BMT.14 The ma-
jority of these studies may be regarded as in-
conclusive with regard to fatigue because spe-
cifically designed instruments assessing fatigue
were not employed. Measuring fatigue by sin-
gle items generally have poor reliability, and a
large number of patients are required in order
to detect quite modest changes of fatigue level.
During recent years, specific fatigue instru-
ments have been developed, and these instru-
ments are preferred in clinical research.15
Fatigue is also a prevalent symptom in the
general population; prevalence rates between
11% to 45% have been reported. In a random-
ized survey in the Norwegian population, 11%
were classified as fatigue cases using the Fa-
tigue Questionnaire (FQ).16 Interpretation of
fatigue data among cancer survivors without
accounting for the high prevalence in the nor-
mal population might invalidate the conclu-
sions. In a recent study of 459 Hodgkin’s dis-
ease survivors (HDS) 12 years post treatment,
the FQ was used. In this cohort, more than
twice as many HDS (26%) were fatigued as
compared to the normal population (11%).17
The pathogeneses of fatigue remain uncer-
tain. Several somatic conditions, such as per-
manent changes in the endocrine or immune
systems, hematological changes, neurologic
impairments, or reduced heart and/or lung
function, may cause fatigue.18 To our knowl-
edge, no one has investigated biological corre-
lates of persisting fatigue among long-term
cancer survivors.19 The possible biological
changes may either be related to the malignant
disease itself or to the side effects from the
treatment. In some studies, fatigue has been
found to be associated with increased levels of
the cytokines interleukin-1 (IL-1) and tumor
necrosis factor (TNF).20–22 Due to the presence
of cytokines in the brain, it has been postu-
lated that they might modulate neural func-
tion, as they are modulators of the immune
system.23 Endocrine causes of cancer-related
fatigue also have not been properly investi-
gated. Although gonadal dysfunction is a well-
known medical complication of ABMT,24 it
has never been correlated with fatigue. Low
testosterone levels in patients with advanced
cancer are found to be common,25,26 but an as-
sociation with fatigue has never been investi-
gated.
The primary aim of this study was to assess
the prevalence of fatigue and HRQL in pa-
tients treated with high dose therapy and
ABMT, and to compare these patients with
norms from the general population. Further-
more, we wanted to explore the relationship
between fatigue and disease and treatment
variables, levels of cytokines, and endocrine ab-
normalities.
Methods
Patients
From 1987 until 1993, all 85 cases of malig-
nant lymphomas requiring ABMT in Norway
were treated at the Norwegian Radium Hospi-
tal. In January 1997, 46 patients were alive, in
complete remission (CR), and invited by mail
to participate in this study. Few studies on late
side effects more than 3 years after ABMT
exist5 and we decided that a follow-up period
of 3 years or more was appropriate to assess
late side effects. One patient refused to see a
new doctor, another answered too late for in-
clusion, and one had moved abroad. Four pa-
tients did not answer. Thirty-eight of the re-
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maining 39 patients completed the mailed
questionnaires. Before the clinical work-up,
three patients declined to participate due to
hospitalization (because of cerebral insult, my-
elodysplastic syndrome, and major psychiatric
problems, respectively). Two of the blood sam-
ples were damaged during transportation.
Thirty-three serum samples were valid for use.
Of 38 patients who returned the question-
naires, the questionnaires from those 33 pa-
tients with valid serum tests were chosen. Of
those 33 patients, 32 completed the entire
quality of life questionnaire and all 33 com-
pleted the entire Fatigue Questionnaire.
Median age at study was 39 years, with a me-
dian observation time since diagnosis of 8
years. Median time since ABMT was 6 years
(Table 1). The majority of the patients were in
stage IVA. Sixteen patients with Burkitts lym-
phoma or lymphoblastic lymphoma received
ABMT as a part of the primary treatment after
a first remission. The remaining 17 patients
with intermediate grade NHL, low grade NHL,
or Hodgkin’s disease received high dose ther-
apy after a second or later remission. It was de-
cided to divide the patients into two groups ac-
cording to these criteria when assessing the
relationship between diagnosis and treatment
to fatigue. All patients received combination
chemotherapy according to standard treat-
ment protocols as part of the induction proce-
dure before the high dose regimen, or as pri-
mary treatment alone. Cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP)
was the most frequently used chemotherapy regi-
men, as primary treatment alone, or in combi-
nation with high dose methotrexate as part of
the preparation procedure. Fourteen of those
16 patients who were treated with high dose
chemotherapy in first remission received high
dose methotrexate as part of the induction
therapy, and eight of them also received meth-
otrexate intrathecally. Cyclophosphamide and
total body irradiation (TBI) was applied as
high dose therapy in 29 patients, and vepecid,
cyclophosphamide, cytosar, BCNU (BEAC) in
4 patients.
Measures
A questionnaire was mailed to the patients.
Non-responders were reminded once through
a telephone call after one week. The question-
naire contained the following measures:
Fatigue Questionnaire (FQ). The Fatigue Ques-
tionnaire is an instrument specifically designed
for assessing fatigue. It was developed for a
hospital study of Chronic Fatigue Syndrome
(CFS),27 and was later refined in a validation
study in which all items specifically related to
CFS were removed.15 Later, it was used in sev-
eral epidemiological studies.16 FQ is a two-
dimensional instrument, consisting of 11 items
measuring physical and mental fatigue. Addi-
tionally, two items ask about the duration and
extent of fatigue symptoms. Each item has four
response categories, scored 0, 1, 2, 3. Total fa-
tigue (TF, all items) (range 0–33), physical fa-
tigue (PF, seven items) (range 0–21) and men-
tal fatigue (MF, four items) (range 0–12) are
the sums of the scores for the whole scale or
the physical and mental subscale, respectively.
The reliability of FQ was assessed by esti-
mates of internal consistencies of the question-
naire. Cronbach’s alpha scores were 0.92 (PF),
0.84 (MF) and 0.89 (TF), confirming the find-
ings of previous validation study.15
European Organization for Research and Therapy of
Cancer (EORTC) QLQ-C30. EORTC QLQ-C30
was used to measure HRQL.9 The instrument
consists of six functional scales that measure
physical, role, cognitive, social, and emotional
function, as well as overall Quality of Life.
Three symptom scales measure fatigue, pain,
and emesis, and six single items measure appe-
tite loss, sleep disturbance, dyspnea, diarrhea,
constipation, and financial impact.
All the scales and item scores were linearly
transformed to 0–100 point scales.28 For the
functional scales and global health/Quality of
Life scale, higher score represents better func-
tioning and quality of life. Higher scores on the
symptom scales correspond to more symptoms.
In two previous studies norms for the FQ
and EORTC QLQ-C30 had been established
from two random surveys of the Norwegian
population.16,29 Significant differences in the
norms according to age and gender were
found.16,29 A decline in physical functioning
and more symptoms were found with increased
age.29 The prevalence and level of fatigue in-
creased with increasing age,16 and women re-
ported worse HRQL and more fatigue than
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men did. Due to the age and gender differ-
ences, an adjustment for these variables was
performed. Responders in the older age
groups, above 60 years, were deleted from the
norms in order to match the ABMT sample,
and a gender-specific stratified analysis was
performed.
Sociodemographics, diagnosis, stage, histol-
ogy, and treatment were based on the patients
records and on the personal interview.
Blood Sampling Protocol
Interleukin 6 (IL-6), TNF and soluble TNF-
p55 and p75 receptor values were determined
in serum samples from blood drawn into ster-
ile vacuum tubes without additives. Tubes were
immediately immersed in melting ice, and se-
rum samples were stored at 
 
70
 
C in multiple
aliquots until analysis. Serum samples for cyto-
kine analysis were frozen and thawed only once.
Measurement of IL-6. IL-6 was determined by
the IL-6 dependent mouse hybridoma cell line
B13.29 clone B9.30 Serial dilutions of serum
samples were incubated for 72 hours with IL-6
dependent cells. Viability was measured in a
calorimetric assay with the MTT tetrazolium
salt (Sigma Chemical Co, St. Louis, Missouri,
USA).31 Recombinant IL-6 was included as a
standard. We preferred the measurement of
IL-6 instead of IL-1 since IL-6 is very stable, and
like IL-1, reflects an immune activation.
Measurement of TNF. TNF was determined by
its cytotoxic effect on the fibrosarcoma cell line
WEHI 164 clone.32 Recombinant TNF was in-
cluded as a standard.
Immunoassays for detection of soluble TNF receptors
(sTNFR) in serum. The TNF receptors p55
and p75 were analyzed by immunoassay.33 Im-
munoplates were coated with the monoclonal
antibodies IV4E and 3H5, recognizing non-
TNF binding sites of p55 and p75 TNFR, re-
spectively. Recombinant human p55 and p75
(provided by Dr. H. Loetscher, F.Hoffmann-La
Roche, Basel, Switzerland) served as standard.
Measurement of soluble TNR receptors bear
Table 1
Patient Characteristics (n
 

 
 33)
n (%)
Age at time of study (yrs) 39 (18-59)a
Age at time of ABMT (yrs) 35 (15-55)a
Gender
Male 18 (55)
Female 15 (45)
Years after diagnosis
3–6 12 (36)
7–10 20 (61)
15–20 1 (3)
Years after high dose chemotherapy
4–6 24 (73)
7–10 9 (27)
Diagnosis
NHL, high grade, 1. remission
(Burkitts lymphoma/Lymphoblastic lymphoma)
16 (49)
NHL, intermediate/low grade /HD
2. or later remission
17 (51)
Clinical stageb (n
 
 30)
I 6 (20)
II 3 (10)
III 7 (23)
IV 14 (47)
Substage (n
 
 29)
A 17 (52)
B 12 (36)
High dose regimen
Cyclophosphamide and TBI 29 (88)
BEAC 4 (12)
a Median (range)
b At time of diagnosis according to Ann Arbor classification. 
HD Hodgkins disease NHL Non Hodgkins Lymphoma.
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some advantage compared to direct quantifica-
tion of TNF. sTNR are very stable, can be de-
termined in stored sera, and allow some in-
sight into TNF biology. Both receptors sTNF
p55 and p75, as well as TNF, are found to be el-
evated in cancer patients.37,38
As reference group for IL-6 and sTNFR p55
and p75, serum samples from 10 healthy indi-
viduals were used. The reference population
was selected in accordance to age and gender
distribution in the patient sample.
Statistical Analysis
Bivariate associations were studied by 2
statistics (nominal categorical variables),
two-tailed t-test (independent samples), or
Pearsons correlation where appropriate. Dif-
ferences in cytokines and cytokines receptor
levels between groups were tested by non-para-
metric tests. Wilcoxon rank sum test (two-
tailed) was used for comparison of the two
groups; the Kruskal-Wallis test was used when
 2 groups were compared. The correlation
coefficients (r) were calculated using Spear-
man’s rank test. A p-value of 0.05 was chosen to
indicate statistical significance. In the analyses
of the EORTC QLQ-C30, a difference above 10
is considered clinically significant,29,34 while 7–10
might be considered as questionably signifi-
cant. In order to interpret differences in mean
estimates of fatigue, a comparison with general
population scores might be used. In a previous
study, we have reported mean differences be-
tween subcohorts of the general population.16
By comparing the most healthy subcohort with
those with poorest health, differences of 3.0,
2.6, and 0.4 were found for TF, PF, and MF, re-
spectively.
Results
Fatigue
Patients cured of malignant lymphoma were
significantly more fatigued than the Norwe-
gian reference population (Table 2). The dif-
ference was most prevalent for physical fatigue.
The mean total fatigue score (TF) was 17.9 and
12.8 among the women and men, respectively
(p  0.02). A similar pattern was found for
physical fatigue (p  0.01), whereas small dif-
ferences between the genders were found in
mental fatigue. Women reported significantly
more physical fatigue and total fatigue as com-
pared to the reference population. For the
male population, no differences were found
between patients and reference population.
Tumor stage or substage at time of diagnosis
was not associated with fatigue, nor was obser-
vation time since treatment or the treatment
burden. Patients treated with high dose che-
motherapy during the second or later remis-
sion who were exposed to a considerable treat-
ment burden did not report significantly more
fatigue than patients treated during the first re-
mission (PF 8.7 vs. 11.3; TF 13.4 vs. 16.9, p 
0.10). A trend was observed, however, among
women. Those treated with high dose chemo-
therapy during the first remission reported
more physical and total fatigue than those
treated during later remissions (PF 14.1 vs. 9.7;
TF 20.8 vs. 14.7; p  0.05 and p  0.07 respec-
tively). The majority (14 of 16 patients) of
these patients received high dose methotrex-
Table 2
Fatigue in Patients and in Reference Population
Females  Males  Total
Fatigue
Patients
Mean (95% CI)
Reference
Population
Mean (95% CI)
Patients
Mean (95% CI)
Reference
Population
Mean (95% CI)
All patients
Mean (95% CI)
Reference
Population
Mean (95% CI)
Physical 12.1a,b (9.6–14.5) 8.0a (7.8–8.2) 8.2b (6.3–10.0) 7.4 (7.2–7.6) 9.9c (8.4–11.5) 7.7c (7.6–7.8)
Mental 5.9 a(4.6–7.2) 4.3a (4.2–4.4) 4.6 (3.5–5.7) 4.3 (4.2–4.3) 5.2c (4.4–6.0) 4.3c (4.2–4.4)
Total 17.9a,c (14.4–21.5) 12.3a (12.1–12.6) 12.8c (10.0–15.5) 11.6 (11.3–11.9) 15.1a (12.9–17.4) 12.0a (11.8–12.2)
n 15 921 18 874 33 1786
a p  0.001 for differences in mean scores between patients and reference population.
b p  0.01 for differences in mean scores between gender.
c p  0.05 for differences in mean scores between gender, and between patients and reference population.
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ate, and eight of them also received methotrexate
intrathecally as part of the preparative regimen.
Health-Related Quality of Life
Patients reported reduced role function,
cognitive function, social function and finan-
cial difficulties compared to the general popu-
lation (Table 3). A questionable reduced glo-
bal quality of life, emotional function and
more dyspnea also were found. Diarrhea was
the only symptom reported more frequently by
the patients. Women reported poorer HRQL
than men when compared to gender-specific
references. The differences between patients
and norms were ten or more in seven scales
and items: global quality of life (women only),
cognitive function (women), emotional func-
tion (women), role and social function (both
genders), diarrhea (women), and financial im-
pact (both genders). Fatigue was equally re-
ported by both genders, and did not differ signif-
icantly compared with the normal population.
Fatigue and Employment Status
Eighteen patients were employed full-time,
whereas 6 and 8 patients, respectively, were
part-time employed or not employed at all
(employment information missing in 3 pa-
tients). Eight of those patients who were partly
or not employed were disabled after the dis-
ease, and 3 patients were getting through their
education. There were clinically and statisti-
cally significant differences in fatigue levels be-
tween those who were employed full-time (PF
8.3, MF 4.7, TF 12.9), employed part-time (PF
10.7, MF 5.3, TF 16.0), and not employed at all
(PF 14.4, MF 6.9 TF 21.3) (p
 
 0.01; 0.05, and
0.02 PF, MF, and TF, respectively). Patients
who were disabled reported more fatigue than
those who were full- or part-time employed (PF
14.4, MF 7.1, TF 21.5).
Endocrine Status
More than half the women had elevated se-
rum levels of follicle-stimulating hormone
(FSH) and leutenizing hormone (LH), while
serum levels of estradiol were decreased in 13
of the females (Table 4). Two women were
postmenopausal, but were not substituted.
Among the men, FSH and LH were elevated in
13 and 6 patients respectively, and low levels of
testosterone were found in 6 patients.
Gonadal dysfunction expressed by high levels
of FSH (
 
20 IU/L for women, 
 
 12 IU/L for
men) and low levels of estradiol (
 
0.33 nmol/l;
women) and testosterone (
 
12 nmol/l; men)
Table 3
EORTC QLQ-C30 Mean Scores by Gender and Age
ABMT
(n
 
 32)
Reference
Population
(n
 
 1404)
ABMT
Female
(n
 
 15)
Female Reference
Population
(n
 
 636)
ABMT
Male
(n
 
 17)
Male Reference
Population
(n  768)
Global QOL (QOL2) 69a 77a 63 75 74 79
Functioning scaled
Physical (PF) 92 95 88 93 95 96
Role (RF) 76b 87b 74 85 76 89
Emotional (EF) 75a 82a 66 79 83 85
Cognitive (CF) 75c 89c 69 88 80 89
Social (SF) 68c 87c 64 85 71 90
Symptom scalee
Fatigue (FA) 34 28 35 32 33 25
Nausea/vomiting (NV) 4 4 7 5 2 3
Pain (PA) 20 18 22 22 19 15
Dyspnea (DY) 19a 11a 18 15 20 13
Insomnia (SL) 20 18 24 21 16 15
Appetite loss (AP) 14 7 16 9 12 6
Constipation (CO) 10 8 9 12 12 5
Diarrhea (DI) 21b 9b 29 9 14 9
Financial difficulties (FI) 22c 9c 27 11 18 7
a p  0.05 for differences in mean scores, patients and reference group.
b p  0.01 for differences in mean scores, patients and reference group.
c p  0.001 for differences in mean scores, patients and reference group.
d Higher scores indicates better functioning.
e Higher scores indicates more symptoms.
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were compared to levels of fatigue to test
whether gonadal dysfunction was related to fa-
tigue among ABMT patients. Nine patients had
reduced ovarian functioning, and the levels of
fatigue did not differ from those with normal
hormone levels (5 patients) (PF 12.6, MF 6.6,
TF 19.1 vs. PF 11.3, MF 4.8, TF 16.2; n.s.). A
similar finding occurred in men with no differ-
ences in fatigue levels between patients with
impaired (n  4) versus males with normal go-
nadal function (n  14) (PF 8.8, MF 4.8, TF
13.5 vs. PF 8.0, MF 4.6, TF 12.6; n.s.)
Thyroid function was not impaired, and only
1 woman and 5 men had a slightly reduced he-
moglobin level. No association between hemo-
globin level and fatigue was found.
Serum Levels of IL-6, TNF, and sTNFR
The serum levels of TNF were below 600 pg/
ml in 31 of 33 patients. Only two male patients
had detectable biological activity of TNF, with
serum levels of 870 pg/ml and 963 pg/ml. The
clinical status and fatigue levels of those pa-
tients did not differ from the rest of the study
population. Serum levels of IL-6, sTNFR-p55,
and sTNFR-p75 were slightly elevated in all
clinical groups of lymphoma patients com-
pared to normal controls (Table 5). A trend
was found in the difference of p75 receptors
with advanced stage (p  0.07). Treatment
burden or time since treatment did not seem
to have any influence on levels of the mea-
sures.
There were no statistically significant corre-
lation between fatigue (TF) and serum levels
of IL-6, TNF, sTNFR-p55, and p75 receptors.
Discussion
The present study demonstrates that fatigue
is highly prevalent in this cohort of long-term
lymphoma survivors treated with ABMT. The
differences in levels of fatigue between the pa-
tient population and the reference group are
highly significant. Among patients cured for
Hodgkin’s disease,17 the level of fatigue was
found to be between the present ABMT cohort
and the reference population. It has been pos-
tulated that fatigue in the HDS survivors may
reduce their quality of life significantly17 and
Table 4
Endocrine Status (Serum Levels) after ABMT
Females
(n  15)
Males
(n  17)
Hb
 11.5 g/dl females 1/15
 13 g/dl male 5/17
TSH  4.0 mIE/l) 1/15
FT4  9 pmol/L) 1/15
FSH
 20 IU/L females 9/15
 12 IU/L males 13/17
LH
 15IU/L females 8/15
 12 IU/l male 6/17
Estradiol  0.33nmol/L 13/15
Testosterone  12 nmol/l 6/17
Table 5
Serum Levels of sTNFRs and IL-6 in Patients Cured of Malignant Lymphoma and Control Groups
(Normal Population)
sTNFR IL–6
p55 median (range) p75 median (range) median (range)
Controls (n  10) 1.05 (0.70–1.50) 1.50 (0.90–2.30) 4.80 (3.20–11.0)
Patients (n  33) 1.39 (0.60–2.20) 1.60 (0.70–2.90) 4.90 (2.70–11.0)
Fatigue levela
high (n  17) 1.30 (0.60–2.20) 1.60 (0.70–2.90) 4.90 (2.70–10.80)
low (n  16) 1.30 (0.60–1.90) 1.60 (0.90–2.40) 5.05 (2.90–11.00)
Burkitts lymphoma/lymphoblastic lymphoma 1.15 (0.30–1.90) 1.45 (0.20–2.40) 5.70 (2.70–11.00)
Intermediate grade/Low grade Lymphoma /HD
Stage
1.30 (1.10–2.20) 1.70 (1.30–2.90) 4.90 (2.70–10.80)
I (n  6) 0.95 (0.80–1.40) 1.25 (0.90–2.00)) 4.50 (3.60–8.30)
II (n  3) 1.30 (0.70–0.60) 1.60 (0.70–1.90) 5.80 (2.70–6.80)
III (n  7) 1.30 (1.10–1.80) 1.80 (1.60–2.30) 4.60 (3.20–10.80)
IV (n  14) 1.25 (0.60–1.90) 1.60 (0.70–2.40) 5.05 (2.70–11.0)
Substage
A (n  17) 1.20 (0.60–1.80) 1.60 (0.70–2.30) 5.40 (2.70–10.80)
B (n  12) 1.30 (0.60–1.90) 1.60 (0.70–2.40) 4.85 (2.70–11.0)
a Mean total fatigue score, high: TF 19.6; mean total fatigue score, low: TF 10.5.
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also reduce their working ability.35 Taking
these findings into consideration, the high
level of fatigue was expected. However, the
findings should be interpreted with caution
due to the relatively small sample size.
A general tendency was found towards re-
duced HRQL as compared to the reference
populations. Similar findings have been re-
ported in several other studies following pa-
tients treated with high-dose therapy.6,7,36
However, the differences in the HRQL are
smaller than for fatigue. This finding may in-
dicate that fatigue is one of the most distress-
ing subjective side effects after ABMT for lym-
phoma.
The fatigue scale within the EORTC QLQ-
C30 did not pick up a significant difference be-
tween the ABMT patients and the reference
population. This finding might indicate that
the 3-item scale within the EORTC QLQ-C30 is
not sensitive enough, or it may measure other
domains of fatigue than the FQ does. The lat-
ter explanation does not seem reasonable be-
cause the content of the EORTC QLQ-C30 fa-
tigue scale is very similar to some of the items
within the physical fatigue scale.
To investigate possible explanations for per-
sisting fatigue, two major lines were followed,
an immunological and an endocrine. Weak re-
lationships were found between serum levels of
sTNFR, TNF, and IL-6 on one hand and fa-
tigue on the other. This was not an unexpected
finding, since the levels of cytokines were not
elevated in our patients. In previous studies, in-
creased levels of cytokines have been found in
patients with malignant lymphoma.37–39
It has been postulated that cytokines may
produce fatigue in humans.20,21,23 In a study of
70 patients with chronic fatigue syndrome
(CFS), immune dysregulation, with particular
focus on dysregulation in TNF expression, was
proposed as a possible biological marker of fa-
tigue.40 The findings in the present study were
consistent with previous data on immune dys-
regulation among patients with CFS.41,42 In an-
other study, elevated serum levels of IL-1 dur-
ing radiotherapy was found in patients with
prostatic cancer at the same time as they re-
ported high level of fatigue.22 In contrast,
Morant43 did not find any correlations between
fatigue on the one hand and TNF, IL-1, IL-2,
IL-6, sIL-1, and sIL-2 on the other. A direct
comparison between our study and the above
mentioned studies might be difficult due to
differences in patient cohort, different meth-
ods of measuring fatigue, and different meth-
ods used to measure cytokines.
Even if no differences were found in levels of
cytokines between patients and controls in our
study, the hypothesis of long-term effects of cy-
tokines on fatigue should not be rejected.
There may be other cytokines of interest, such
as IL-1 and IL-2. The effects on the central ner-
vous system, on muscles, and on the endocrine
system after long-term exposure of cytokines
would be of special interest to investigate in
the oncology population.
A gender difference has been shown for
fatigue16 and HRQL29 in the reference popula-
tion. In the ABMT cohort, the gender differ-
ences were large compared to the findings in
the normal population. The gender differ-
ences were most pronounced for physical fa-
tigue, which was reported by women to be sig-
nificantly higher than men. The explanation
for this difference is unknown. It might theo-
retically be related to both biological and/or
psychological factors.
A highly significant difference also was ob-
served in the younger female group (15–39
years) compared to women aged 40–60 years.
Gonadal dysfunction with elevated FSH and re-
duced levels of estradiol was found in the major-
ity of the women, but an association with fatigue
failed to appear. From a clinical perspective, the
high prevalence of ovarian dysfunction is of
great importance. Loss of ovarian function oc-
curs in all women immediately after autologous
and allogenic bone marrow transplantation
and is caused by injuries to the ovaries.44 In a
recent study, recovery of ovarian function was
found in one-third of the patients, and was pre-
dicted by younger age. Total body irradiation
(TBI), however, seemed to have a negative ef-
fect on recovery of ovarian function.24 In our
study population, 93% of the women (n  14)
received TBI and cyclophosphamide, one of
the most toxic regimens for ovaries. The lack
of association between fatigue and the endo-
crine function in our patients may be due to a
combination of the very high prevalence of fa-
tigue and reduced gonadal function, and a
very small sample size. It would also have been
of interest to measure testosterone among the
women. It is likely that testosterone levels are
impaired in women with gonadal dysfunction.
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Long-term hormone therapy with estradiol
and testosterone is reported to have a positive
effect on loss of energy in some women.45 The
findings suggest further follow-up studies of
cancer survivors, which should measure the de-
velopment of fatigue and altered gonadal func-
tion over time.
Neurotoxicity is an important issue for survi-
vors after high-dose therapy. In several studies,
cognitive impairments have been associated
with TBI4,48 as well as with high-dose chemo-
therapy.3 Methotrexate is considered to be
one of the most neurotoxic drugs. Reduced
cognitive functioning among cancer survivors
has been reported in several studies46,47 and
may be related to fatigue, especially mental fa-
tigue. In our study, cognitive function, as mea-
sured by the EORTC-QLQ-C30, was signifi-
cantly reduced compared to the general
population (Table 3), and correlated signifi-
cantly with fatigue (r  0.52, p  0.01; data not
presented). In a cross-sectional study, it might
be difficult to determine whether cognitive im-
pairments are related to the treatment or to
pre-existing cognitive problems. However, half
of the patients received high-dose methotrex-
ate, and some also received methotrexate in-
trathecally before the ABMT. Patients who re-
ceived high-dose methotrexate as a preparative
regimen were more fatigued and reported re-
duced cognitive functioning, as compared to
patients who did not receive this type of treat-
ment. Cognitive function items are increas-
ingly included in quality of life measures. The
validity of a brief cognitive function scale, like
the one included in EORTC-QLQ-C30, is ques-
tioned.46 Studies among cured lymphoma pa-
tients have shown that their reports of memory
and concentration problems appear to reflect
affective disorder and mental fatigue. Using
well validated objective neuropsychological
tests is recommended for assessing higher
mental function.3,47
In the absence of information about psychi-
atric distress, this study is somewhat limited by
the uncertainty of the constitution of fatigue. A
relation between negative affect and fatigue
has been suggested, and depression in particu-
lar is considered to be a contributor to fatigue.35
In a study of Hodgkin’s disease survivors,
chronic fatigue was associated with increased
levels of anxiety and depression.49 However, no
association between previous psychiatric mor-
bidity and fatigue was found. In our study, we
found moderate correlation between fatigue
and mental distress assessed by EORTC-QLQ-
C30 (r  0.63, 0.52, and 0.62, PF, MF, and
TF, respectively; p  0.01). The relationship
between fatigue and psychiatric distress is far
from clear. Both biological correlates and the
relation to psychiatric disorders should be ex-
plored in further studies of fatigue in cancer
patients.
This study has shed light on a prevalent, but
poorly understood, phenomena—fatigue—in
patients cured of cancer. Fatigue is multidi-
mensional, and the pathophysiology remains
uncertain. Significant endocrinological or im-
munological associations with fatigue could
not be demonstrated in the present study. Be-
cause high-dose chemotherapy for cancer aims
to achieve long-term survival and should allow
patients to regain an acceptable life style after
completion of treatment, recognition and in-
vestigation of fatigue after cancer treatment
should be addressed in future research.
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Appendices
EORTC QLQ-C30
Vi er interessert i forhold vedrørende deg og din helse. Vær så vennlig å besvare hvert 
spørsmål ved å sette en ring rundt det tallet som best beskriver din tilstand. Det er ingen 
"riktige" eller "gale" svar. Alle opplysningene vil bli behandlet konfidensielt. 
Nei Ja
1. Har du vanskeligheter med å utføre anstrengende aktiviteter, 
 slik som å bære en tung handlekurv eller en koffert? 1 2 
2. Har du vanskeligheter med å gå en lang tur? 1 2 
3. Har du vanskeligheter med å gå en kort tur utendørs?  1 2 
4.  Er du nødt til å ligge til sengs eller sitte i en stol det meste av dagen? 1 2 
5. Trenger du hjelp til å spise, kle på deg, vaske deg eller gå på toalettet? 1 2 
6.  Er du redusert på noen måte slik at du ikke kan arbeide eller gjøre husarbeid? 1 2 
7.  Er du helt ute av stand til å arbeide eller gjøre husarbeid? 1 2 
I løpet av den siste uka: Ikke i det 
hele tatt Litt Endel
Svært
mye
8. Har du vært tung i pusten? 1 2 3 4 
9.  Har du hatt smerter? 1 2 3 4 
10. Har du hatt behov for å hvile? 1 2 3 4 
11. Har du hatt søvnproblemer? 1 2 3 4 
12. Har du følt deg slapp? 1 2 3 4 
13. Har du hatt dårlig matlyst? 1 2 3 4 
14. Har du vært kvalm? 1 2 3 4 
15. Har du kastet opp? 1 2 3 4 
16. Har du hatt treg mage? 1 2 3 4 
17. Har du hatt løs mage? 1 2 3 4 
Bla om til neste side
I løpet av den siste uka: Ikke i det 
hele tatt Litt Endel
Svært
mye
18. Har du følt deg trett? 1 2 3 4 
19. Har smerter påvirket dine daglige aktiviteter? 1 2 3 4 
20. Har du hatt problemer med å konsentrere deg, 
 f.eks. med å lese en avis eller se på TV? 1 2 3 4 
21. Har du følt deg anspent? 1 2 3 4 
22. Har du følt deg engstelig? 1 2 3 4 
23. Har du følt deg irritabel? 1 2 3 4 
24. Har du følt deg deprimert? 1 2 3 4 
25. Har du hatt problemer med å huske ting? 1 2 3 4 
26. Har din fysiske tilstand eller medisinske behandling 
 påvirket ditt familieliv? 1 2 3 4 
27. Har din fysiske tilstand eller medisinske behandling 
 påvirket dine sosiale aktiviteter? 1 2 3 4 
28. Har din fysiske tilstand eller medisinske behandling 
 gitt deg økonomiske problemer? 1 2 3 4 
Som svar på de neste spørsmålene sett en ring rundt det tallet fra 1 til 7 som best 
beskriver din tilstand 
29. Hvordan har din fysiske tilstand vært i løpet av den siste uka? 
 1 2 3 4 5 6 7 
 Svært dårlig      Helt utmerket 
30. Hvordan har livskvaliteten din vært i løpet av den siste uka? 
 1 2 3 4 5 6 7 
 Svært dårlig      Helt utmerket 
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Fatigue
Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måned. Vennligst
besvar alle spørsmålene ved å krysse av for det svaret du synes passer best for deg. Vi ønsker at du besvarer
alle spørsmålene selv om du ikke har hatt slike problemer. Vi spør om hvordan du har følt deg i det siste og
ikke hvordan du følte deg for lenge siden. Hvis du har følt deg sliten lenge, ber vi om at du sammenligner
deg med hvordan du følte deg sist du var bra. Sett kun ett kryss for hvert spørsmål.
Vennligst  kontroller at du har besvart alle spørsmålene
Dato for utfylling: . .
Har du problemer med at du føler deg sliten?
Trenger du mer hvile?
Føler du deg søvnig eller døsig?
Har du problemer med å komme i gang med ting?
Mangler du overskudd?
Har du redusert styrke i musklene dine?
Føler du deg svak?
Har du vansker med å konsentrere deg?
Forsnakker du deg i samtaler?
Er det vanskeligere å finne det rette ordet?
Hvordan er hukommelsen din?
Hvis du føler deg sliten for tiden, omtrent hvor
lenge har det vart? (ett kryss)
Hvis du føler deg sliten for tiden, omtrent hvor
mye av tiden kjenner du det? (ett kryss)
Mindre enn
vanlig
Mindre enn
vanlig
Mindre enn
vanlig
Mindre enn
vanlig
Mindre enn
vanlig
Mindre enn
vanlig
Bedre enn
vanlig
Nei, mindre
enn vanlig
Mindre enn
vanlig
Ikke i det
hele tatt
Ikke i det
hele tatt
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Ikke mer
enn vanlig
Som vanlig
Som vanlig
Ikke verre
enn vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Mer enn
vanlig
Verre enn
vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye mer
enn vanlig
Mye verre
enn vanlig
Mindre enn en uke
Mindre enn tre måneder
Mellom tre og seks måneder
Seks måneder eller mer
25% av tiden
50% av tiden
75% av tiden
Hele tiden
Mnd ÅrDag
Pasient nr.
Draft

2. Jeg gleder meg fortsatt over ting jeg pleide å
glede meg over
Her kommer noen spørsmål om hvordan du har følt deg den siste uken. Sett bare et kryss for hvert spørsmål. Ikke tenk for
lenge på svaret - det er din umiddelbare reaksjon på hvert spørsmål som er interessant.
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
3. Jeg har en urofølelse som om noe forferdelig
kommer til å skje
Helt sikkert og svært ille
Ja, men ikke så veldig ille
Litt ille, men det bekymrer meg ikke så mye
Ikke i det hele tatt
4. Jeg kan le og se det morsomme i situasjoner
Like mye som jeg alltid har gjort
Ikke like mye nå som før
Avgjort ikke så mye nå som før
Ikke i det hele tatt
5. Jeg har hodet fullt av bekymringer
Veldig ofte
Ganske ofte
Av og til
En gang i blant
6. Jeg er i godt humør
Aldri
Noen ganger
Ganske ofte
For det meste
7. Jeg kan sitte i fred og ro og kjenne meg
avslappet
Ja, helt klart
Vanligvis
Ikke så ofte
Ikke i det hele tatt
8. Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
9. Jeg føler meg urolig liksom jeg har sommerfugler i
magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
10. Jeg har sluttet å bry meg om hvordan jeg ser ut
Ja, helt klart
Jeg bryr meg ikke så mye som jeg burde
Det kan nok hende jeg ikke bryr meg nok
Jeg bryr meg om utseendet like mye som jeg alltid har gjort
11. Jeg føler meg rastløs som om jeg stadig må være i
aktivitet
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
12. Jeg ser med glede frem til hendelser og ting:
Like mye som jeg alltid har gjort
Heller mindre enn jeg pleier
Avgjort mindre enn jeg pleier
Nesten ikke i det hele tatt
13. Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Svært ofte
Ikke så veldig ofte
Ikke i det hele tatt
14. Jeg kan glede meg over en god bok eller et radio
eller et TVprogram
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden
1. Jeg er nervøs eller anspent
For det meste
Ofte
Noen ganger
Ikke i det hele tatt
HADS Dato(dd.mm.åå)Pasientnr.Studienr.
Skjema utarbeidet ved Enhet for anvendt klinisk forskning / Kontor for klinisk kreftforskning
Tlf.: 73 86 72 71/73 86 84 44
40040

Karnofsky Index
Kriterier for aktivitesstatus ved skjelettmetastatisk kreftsykdom
Utfører normal aktivitet,
trenger ikke spesielt stell
Ute av stand til å arbeide.
Klarer seg hjemme, greier
personlig stell. Trenger
varierende grad av hjelp.
Ute av stand til å greie seg
selv. Avhengig av pleie.
Sykdommen i progresjon.
Normal. Ingen plager eller subjektive tegn på
sykdom.
Klarer normal aktivitet, sykdommen gir lite
symptomer.
Klarer med nød normal aktivitet.
Sykdommen gir en del symptomer.
Klarer seg selv, ute av stand til normal aktivitet
aller aktivt arbeid.
Trenger noe hjelp, men klarer stort sett å
tilfredstille egne behov.
Trenger betydelig hjelp og stadig medisinsk
omsorg.
Ufør, trenger spesiell hjelp og omsorg.
Helt ufør, hospitalisering nødvendig, men fare
for død er ikke overhengende.
Svært syk, hospitalisering og understøttende
behandling nødvendig.
Moribund, dødsprosessen er i rask fremmarsj.
Død
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Draft

Dissertations at the Faculty of Medicine, NTNU
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